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INTRODUCTION
Few areas in medicine can equal the rapid
proliferation of information that has occurred and
continues to occw;. in •. the area of human reproduc
tion. The progress in our understanding of the
underlying mechanisms which control the human
female reproductive system has led to an ever
increasing refinement in the definition of pathologic
states and the development of specific, effective
therapeutic agents for some of these. It is clear
that not all is yet known and that there is need
for repetitive reassessment of our knowledge in order
to keep abreast of these rapid discoveries. Preg
nancy, once achieved, is subject to yet another sys
tem of hazards about which a great deal has been
learned. Both maternal and fetal diseases have
become better understood through more refined
diagnostic methods. More specific and successful
methods of management have been designed. The
improvement in the outcome of these high-risk
pregnancies can now be demonstrated, but it does
require up-to-date knowledge and skills on the part
of the physician and a constant effort against the
social and economic obstacles which prevent optimal
care. With the occurrence of malignant change in
the reproductive organs, a new set of hazards is ex
perienced. The admirable degree of international
cooperation among gynecologic oncologists with
common staging systems and controlled therapeutic
studies has led to rapid improvement in cure
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rates of most, but not all, gynecologic malignancies.
Periodic review of present therapeutic modalities,
newer (and generally more conservative) modalities,
and the accumulated epidemiologic data is of im
portance in keeping us oriented. Understanding of
gynecologic malignancies has contributed much to
our understanding of many similar malignancies.
Not all the changes which are occurring can
be reviewed within the scope of this conference.
However, we are indeed fortunate to be able to
learn the most current information from recog
nized leaders in their specific field. We are most
grateful to our guest lecturers who interrupted their
busy and productive lives to come to Richmond
to share their knowledge with us and to our MCV
faculty for their participation.
Our special thanks to Dr. Saul B. Gusberg
who was the 46th McGuire Lecturer and to Dr.
Robert A. Munsick, our second H. Hudnall Ware,
Jr. Visiting Professor. We would also like to recog
nize the H. Hudnall Ware, Jr. Society and its
president. Dr. Louis Keffer, for their sponsorship
and participation.
LEO J. DUNN, M.D.
Professor and Chairman
Department of Obstetrics and Gynecology
Medical College of Virginia
Virginia Commonwealth University

Modern Management of Diabetic Pregnancies*
ELSIE R. CARRINGTON, M.D.
Professor and Chairman, Department of Obstetrics and Gynecology.
Medical College of Pennsylvania, Philadelphia. Pennsylvania

On a broad national basis. it should be quite
possible to substantially reduce maternal morbidity
and the disproportionately high numbers of perinatal
losses associated with diabetic pregnancies. Nation
wide, the overall perinatal mortality rate for this
group is approximately 20%. which is at least double
that incurred in centers where intensive care facilities
and personnel are available. and consistent, well
coordinated care by the health team is provided.
Although the prognosis for fetal survival is less
favorable with advances in severity of the diabetic
state. there is a significant risk even during the
mildest stage of the disease. Careful prospective
studies. notably those of O'Sullivan and his group.
have demonstrated that gestational diabetics have a
higher than normal perinatal mortality. Prevention
begins with diagnosis.
Detection. Ideally, a two-hour postprandial
screening of blood sugar following a 100 g
carbohydrate-equivalent breakfast should be a stan
dard prenatal laboratory test. In practicality. all
patients with a poor obstetric history, previous
perinatal losses, large babies, a family history of
diabetes. glycosuria, or significant obesity are can
didates for a glucose tolerance test. Using these
criteria, we subjected 3,340 prenatal patients to the
three-hour glucose tolerance test following a 100 g
glucose load, and 540 showed abnormal responses.
The yield of positives, therefore, was I in 6.3 suspects,
and the overall incidence of gestational diabetes in
this Philadelphia population was 1.18%. Criteria used
are as follows: fasting = 90 mg %: I hour = 165 mg
• The following summarizes 1he main points of a leclure
presented by Dr. Carringlon al the 46th Annual McGuire Leclure
Series. December 5. 1974, al the Medical College of Virginia. Rich
mond.
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%: 2 hour = 145 mg %: 3 hour = 125 mg%. Glucose
tolerance is impaired if two or more of these values
are equaled or exceeded. The test is performed on
whole blood using the Somogyi method or
autoanalyzer (Hoffman) method. If plasma or serum
is used. 10 mg % should be added to each of the
values. The importance of a very large screening
program was shown in the prospective study con
ducted by O'Sullivan and his group who found that
screening is particularly important in the obese,
older-age patient. Perinatal mortality was 1.5% for
normal control patients and 6.4% for those with
gestational diabetes. The increase in perinatal loss
was strikingly evident in gestational diabetic mothers
25 years of age or older, with the risk further in
creased by obesity.
Metabolic Control. How strict should this be'1
These patients are ketosis prone. Ketosis is one of the
most lethal events for the fetus. but one of the most
preventable complications for the mother. The in
cidence of intrauterine fetal death is greatly increased
in pregnancies complicated by pre-coma maternal
acidosis. Of further concern is the fact that the
National Collaborative Study reveals a significant
relationship between maternal ketonuria and central
nervous system defects or deficiencies in the off
spring. Neither insulin treatment nor hypoglycemia
shows a positive association. For these reasons the
patient should be kept as nearly normoglycemic as
possible and free of ketonuria even at the expense
of an occasional episode of hypoglycemia which is
readily controlled.
Many, but not all, gestational diabetics can be
maintained on diet alone. The response to diet is
determined on the basis of a two-hour postprandial
blood sugar obtained at two-week intervals. If the
5
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two-hour value on diet cannot be maintained below
160 mg%, the patient needs insulin, and for the pur
pose of management of the pregnancy such patients
should be considered in the insulin-dependent cate
gory.
Is there any advantage in treating all gestational
diabetics with low-dose insulin? Several groups in this
country and abroad have compared treated and un
treated cases. Apart from slight reduction in over
sized infants, other advantages are not yet sufficiently
clear-cut to warrant recommending this approach.
Oral hypoglycemic agents should not be used in
pregnancy. In contrast to insulin, the sulfonyl ureas
pass the placental barrier readily. Neonatal hepatic
function is relatively immature, and the newborn
metabolizes these drugs poorly. Intractable
hypoglycemia persisting as long as the eleventh day
of life, and in some instances requiring exchange
transfusion, have been reported, particularly in rela
tion to long-acting preparations such as chlor
propamide. The biguanides which raise the blood lac
tate level may accentuate the tendency to maternal
ketoacidosis and are contraindicated during pregnan
cy.
The anti-insulin effects of pregnancy usually
cause significant changes in insulin needs after the
20 th week of gestation. The rise in requirement is
sometimes precipitous about the 24th to 26th week.
Both the patient and the physician should be on the
lookout for these changes. In our patients, 75% needed
a mean of about 60% more insulin. Twenty-three
percent showed only minor increase in insulin
requirement. Only an occasional patient showed
reduction in insulin need.
One of the poorly understood problems has to
do with remission, which may occur particularly in
the early stages of diabetes. How does one handle the
patient who states that she had an abnormal glucose
tolerance test with her previous pregnancy and was
treated accordingly, but the glucose tolerance test in
the present pregnancy is normal? While it is the rule
that the diabetic state will progress, remissions do oc
cur. We have encountered this phenomenon in a
number of gestational diabetics and in one case of
f
juvenile diabetes. Since the adverse ef ect upon the
fetus can occur al any stage including the prediabetic
period, it is important to accept the reality of remis
sion and to avoid the temptation to ascribe its oc
currence to faulty initial diagnosis.
Most diabetics have some degree of hydramnios,
excessive in approximately 10% of cases. The com-

mon practice of prophylactic use of diuretic and
rigid salt restriction may do more harm than good.
Thiazides are useful only in otherwise uncompli
cated fluid retention. If administered alternately
three days on and three days off, these drugs will
often reverse simple fluid shifts without disturbing
electrolyte balance, but they are ineffectual for re
versal of toxemia or hydramnios. Hospitalization
is necessary if these conditions develop. Asympto
matic bacteriuria is found in about 12 or 13% of
diabetic pregnancies, or approximately twice the
overall incidence, and should be treated when
found.
Prenatal Monitoring. The ability to predict in
trauterine fetal deaths in diabetic pregnancies on
clinical evidence alone has limitations. A reliable
method for assessing intrauterine fetal welfare should
be available in every diabetic pregnancy. Although
no single test is capable of detecting all types of
malfunctions that affect the fetus, the urine estriol
test is, in our experience, indispensable. The fact
that estriol production requires a fetal as well as a
placental component is an obvious advantage. The
types of cases in which estriol values may be mis
leading are small in number and can usually be
readily identified. These are mainly cases in which
renal function is markedly reduced and renal clear
ance of estriol diminished.
Although the majority of patients with mild
diabetes can be maintained free of complications and
await labor at term, some cannot. Fetal deaths do oc
cur in the virtually asymptomatic, well-controlled
gestational diabetic pregnancy. In these cases, estriol
determinations have proved to be of great value in
identifying the fetus in jeopardy who should be
delivered and, on the other hand, in providing
reassurance and safe conduct through the natural
course of pregnancy when estriol values remain in the
normal range.
Recent recommendations have been made to
apply the same principles to pregnancies complicated
by overt diabetes. While it is feasible to individualize
and extend the timing of delivery to the 38th week
or even beyond in many cases of B and C insulin
dependent diabetics, those with advanced disease are
poor candidates for this approach, even with frequent
monitoring. From a practical point of view, and
purely on clinical grounds, pregnancy in a patient
with angiopathy, retinopathy, or nephropathy can
rarely be carried beyond the 37th week, and all too
often the pregnancy has to be terminated before that
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optimal time in the interest of the mother or baby or
both. The suddenness with which serious changes or
events can take place in these patients and the fact
that methods for determining fetal maturity are
available (particularly the lecithin/sphingomyelin
ratio and the creatinine concentration) offset the
possible advantages of attempting to extend the
gestational period for Classes D. E. and F diabetics
beyond 37 weeks.
The infant of a diabetic mother is at risk from
the moment of birth. Respiratory distress is the
greatest threat. It is most directly related to
prematurity and accentuated in diabetes. While tests
for fetal maturity should make iatrogenic prematuri
ty preventable, early delivery will continue to be
necessary in selected cases to avoid intrauterine fetal
death or damage. The neonatologist experienced in
dealing with respiratory pathophysiology who can
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initiate treatment within minutes after birth, and a
neonatal intensive care unit capable of providing
clinical and laboratory support services on a 24hour-a-day basis offer the best chance for intact
survival.
In principle. the problems of diabetic pregnan
cies do not differ from the problems of at least two
thirds of all high-risk pregnancies, and in this respect,
they serve as a prototype for centralized perinatal
care. The demands in terms of medical and
paramedical manpower. the high cost of services and
facilities comprising the perinatal center, and the con
cern for quality of life will surely require revision of
the current health care delivery system. Consolida
tion of scarce resources in centers. whether teaching
or community hospitals. capable of providing
specialized care for the high-risk mother and new
born is the logical approach.

The Endocrinologic Evaluation of
Amenorrhea* **
CHARLES B. HAMMOND, M.D., R. HERBERT WIEBE, M.D..
LEE TYREY, PH.D., DAVID W. SCHOMBERG, PH.D.
Division of Endocrinology and lnfenility, Department of Obstetrics and
Gynecology, Duke University Medical Center, Durham, North Carolina

Introduction. The purpose of this paper is to
review the endocrinologic evaluation of 58 patients
who presented to our institution this past year with a
chief complaint of absent or irregular menses. The
primary goal for presenting these patients is to review
the results of several newer studies as well as older
and more classical studies which are useful in the
differential diagnosis of amenorrhea. Such newer
studies not only take advantage of the more current
knowledge of the ovulatory process but also utilize
recently developed and highly sensitive techniques or
hormonal assay. It is hoped that this will provide the
reader with some suggestions for a current and
efficient method to evaluate the several causes or
amenorrhea.
Materials and Methods. Amenorrhea is usually
categorized as being either primary or secondary. and
the patient's age or duration of absent menses varies
among the several definitions available. For the pur
pose of this paper the following definitions will be
utilized:
Primary Amenorrhea. Failure to have initiated
menstrual bleeding by age 18.
Secondary Amenorrhea. Cessation of previously
established menses for an interval of more than one
year.
0/igomenorrhea. Spontaneous, irregular menses
* Presented by Dr. Hammond al the 46th Annual McGuire
Lecture Series. December 5. 1974. al the Medical College of
Virginia, Richmond.
** Supported by a grant (RR-30) rrom the General Clinical
Research Ccnlers Progr..im of the Division of Research Resources.
National Institute or Health.
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occurring at intervals of not less than three months.
Fifty-eight patients were studied and were divid
ed into three major diagnostic categories according to
their presenting menstrual patterns. Eight patients
had primary amenorrhea, forty-six had secondary
amenorrhea. and four patients had oligomenorrhea.
Other patients with demonstrable uterine causes of
amenorrhea are excluded from this study. This in
cluded patients with Asherman's syndrome, miil
lerian abnormalities in which no uterus was pres
ent. and testicular-feminization patients. Thus, all
patients included had uteri capable of normal
menstruation, and this was evidenced by proges
terone-induced withdrawal bleeding, endometrial bi
opsy, estrogen-progesterone withdrawal bleeding,
and/or hysterosalpingogram. Patients with easily diag
nosable abnormalities of thyroid or adrenal function
also are not included, as early outpatient studies usually
revealed the etiology of their amenorrhea and ap
propriate therapy resulted in prompt return of menstrual
function. For these reasons one can not draw valid
incidence frequencies from this referral-practice popula
tion of 58 amenorrheic patients.
S1udies Performed. All 58 patients were
hospitalized on the Clinical Research Ward of our
institution and underwent study. Tests included
a thorough general and endocrine history, com
plete physical and pelvic examination, Papanicolaou
smear. vaginal cytologic maturation index. complete
blood count. urinalysis. Chem- I 8. anteroposterior
(AP) and lateral skull x-rays. chest x-ray. and visual
fields by perimeter.
All 58 patients also underwent a series or
MCVQUARTERLY 11(1):8-14. 1975
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baseline and dynamic hormonal testing. Serum total
estrogen (I). progesterone (2), follicle stimulating
hormone (FSH) (3). luteinizing hormone (LH) (4),
I and growth hormone (5) were all performed in
duplicate by standard radioimmunoassay techniques.
Serum prolactin was initially done in the labora
tory or Dr. Henry Friesen and later by Dr. Stuart
Handwerger, both using radioimmunoassay (6).
Serum T, and T3 Uptake were done by standard
techniques, as were urinary 17-hydroxycorlicoids and
17-ketosteroids.
All patients also underwent the following three
dynamic tests of pituitary function:
I. Hypoglycemia was induced by the intra
venous administration of 0.1 units insulin per
kilogram with blood glucose and human growth hor
mone (radioimmunoassay) determined at intervals
over 90 minutes. Blood glucose had to achieve at least
50% reduction from fasting levels to be considered an
adequate stimulus for the release of growth hormone.
A positive growth hormone response to insulin
induced hypoglycemia consisted of a peak value or
growth hormone greater than IO ng/ml (7).
2. Control 24-hour urine collections were ob
tained for 17-hydroxycorticoids (170H) and 17ketosteroids (I 7KS). If normal hydroxycorticoids
were present. the patient was then given
Metopirone". 750 mg orally every 4 hours for 6
doses. After the last dose of Metopirone•. another
24-hour urine collection was made. A normal re
sponse of pituitary ACTH was considered present
if the levels of 17-hydroxycorticoids doubled (8).
3. The ability to release gonadotropins was
tested with LH-FSH Releasing Hormone. Baseline
FSH and LH were determined. then the patients
received 100 µg SC of AY 24031, Ayerst Labora
tories LH-FSH Releasing Hormone. Blood samples
were then taken at frequent intervals over a period
of 6 hours, and duplicate samples were assayed by
radioimmunoassay for FSH and LH. Serum total
estrogens were determined by radioimmunoassay on
the control and 6-hours samples. Currently we are
evaluating a variety of response parameters. and we
realize that our own criteria for a positive response
may be altered. However, in the interim. a positive
response to LH-FSH Releasing Hormone was con
sidered present if both serum LH rose by more than
fourfold over baseline and serum FSH at least
doubled (9).
Other Studies. As patients were evaluated by the
techniques listed previously, many were found to
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have significant abnormalities which required further
investigation. Such studies included:
Patients with prolactin excess (on duplicate
samples) usually underwent further testing of prolac
tin kinetics with L-dopa, chlorpromazine, water load,
and other studies. If the excess secretion was not
readily explainable. then sella turcica tomography
and pneumoencephalography were usually per
formed.
Evidence or clinical androgen excess or signifi
cant laboratory documentation of this usually led to
determination of serum testosterone, urinary
pregnanetriol. and appropriate dexamethasone sup
pression. If an ovarian source was presumed, then
laparoscopy and ovarian biopsy were carried out.
Elevated 17-hydroxycorticoids led to the deter
mination of plasma cortisol and dexamethasone sup
pression. with pituitary evaluation if pituitary tumor
was suspected.
Abnormal thyroid function was evaluated by
traditional methodology.
Patients who had stigmata of gonadal dysgene
sis. or primary amenorrhea which seemed of gonadal
origin (such as evidenced by elevated gonadotropins),
were then evaluated by buccal smear and karyotype
of peripheral leukocytes. If there was evidence or
signif-icant early estrogen production or a "Y"
chromosome on karyotype. then laparoscopy and
gonadal biopsy with both histopathologic study and
gonadal karyotype were done. Gonads with "Y"
chromosome were surgically removed.
If patients had abnormal skull x-rays or signifi
cant endocrinologic evidence of hypopituitarism or
pituitary tumor. then tomograms of the sella turcica,
pneumoencephalography. and/or carotid arteriography
were performed.
Once a diagnosis was achieved. appropriate
therapy was carried out. No patient suffered any
significant side effects from any of these diagnostic
studies.
Results. After these 58 patients had completed
the previously listed diagnostic studies. a final
diagnosis was assigned. The tables which follow
(Tables I. 2. 3) are each arranged with patients
grouped by these final diagnoses and the results
of the various diagnostic tests listed below. In this
fashion one can not only study the results of the
several tests performed in patients with a particular
cause of amenorrhea but also evaluate how a specific
test may provide useful data in the several groups of
patient diagnoses.
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TABLE I
Primary Amenorrhea

( 8 Patients)

Diagnosis

(No.)

Family Hx.

Constitutional
Delay
(3)

Hypothalamic

+

-

Cause
(2)

?Congcnit..tl

Gonadal

Abscncc LH
(2)

Dysgenesis
(I)

Estrogen

I

J sl.

I

I

FSH-LH

FSH-Normal
LH-sl. I

FSH-Normal
LH-sl. I

FSH-Normal
LH-sl. I

II

-

-

-

-

FSH +
LH +

FSH +
LH +

FSH +
LH -

FSH +
LH +

lnsulin-HGH

+

+

+

+

Metopirone k

+

+

+

+

HGH. Prolactin.
170H. 17KS.
Thyroid
LRH Test

+ positive response. or normal test result.
- negative response. or reduced test result.
(See lex! for details.)

Primary Amenorrhea (Table I). Eight patients
presented with primary amenorrhea. Three patients
were felt to have constitutional delay of menarche.
Family history was positive in all three patients, and.
while all had had a sequential development of secon
dary sex characteristics. all had reduced estrogen
levels. Levels of FSH were normal and LH levels
were minimally elevated in all three patients. Baseline
testing of other hormones was normal. There was a
significant response in all patients to LH Releas
ing Hormone, Insulin-Growth Hormone, and Met
opirone®. The patients' ages were 18, 19, and 23
years. All have subsequently begun spontaneous
menses.
Similar findings to those mentioned in the
previous category were present in the testing of two
patients thought to have "hypothalamic" primary
amenorrhea. except there was no family history of
delayed menarche.
Two patients had low baseline serum LH and
failed to elevate LH in response to LH-Releasing
Hormone on either of two occasions. This suggested
lo us a reduced ability to produce, or release, or a
congenital diminution in LH.
Finally, one patient had Turner's syndrome
(gonadal dysgenesis) which was proven by karyotype.
Serum FSH was quite high, but there still existed a
capacity of the pituitary to increase gonadotropin
release when LH-Releasing Hormone was given.

Secondary Amenorrhea-Organic (Table 2). Six
teen patients presented with secondary amenorrhea
which was finally shown to be of an organic etiology.
Four patients had pituitary tumors; one, a
patient with a microadenoma and hyperprolac
tinemia. one with clinical signs of acromegaly. Three
of the four patients had abnormal skull x-rays and
reduced estrogen production. Two patients had
significantly low gonadotropin values. Baseline hor
monal testing revealed an elevation of growth hor
mone in the patient with acromegaly. Other baseline
testing was normal. Two of the four patients failed to
have an adequate response by LH (one borderline,
however) while two had a positive response of FSH
to LH-Releasing Hormone. One of the four patients
had a negative growth hormone test. All had surgical
ly proven lesions.
Two patients had craniopharyngiomas. Both
had positive skull x-rays and decreased estrogen and
gonadotropins. One patient had reduced baseline 17hydroxycorticoids. One patient had a modest
response to LH-Releasing Hormone while the other
had no response. Neither patient responded to
lnsulin-HGH testing. Metopirone® testing was not
done in one patient. but ACTH testing was normal.
Two patients had the "empty sella" syndrome.
Again. skull x-rays were abnormal in both patients
and estrogen and gonadotropins were low. Other
baseline hormonal testing was normal. Both patients
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responded to Insulin-HGH and Metopirone'''. but
one patient responded poorly to LH-Releasing
Hormone. Both patients had this diagnosis con
firmed by pneumoencephalography.
Two patients had Sheehan's syndrome with
postpartum pituitary necrosis. One patient was
clinically panhypopituitary. finding conf-irmed by low
test results of estrogen, gonadotropins. thyroid, and
adrenal function. Neither patient responded positive
ly with both LH and FSH to LH-Releasing Hormone
or Insulin-HGH. Metopirone• testing was not per
formed when low serum cortisols were detected.
Adrenal response to ACTH was normal.
Four patients had clinical signs of androgen ex
cess with significant hirsutism. Clinical estrogeniza
tion was good in all four. but, while ba:;eline FSH
was normal, the baseline LH was mildly elevated in
all. Laboratory evidence of excess androgen was pres
ent in all four patients and was reflected by elevated
17-ketosteroids. Serum testosterone was elevated in
two patients with Stein-Leventhal syndrome. and
pregnanetriols were elevated in the other two patients

Diagnosis
(No.)
P. Exam

Skull x-ray
Estrogen
FSH-LH
HGH. Prolactin, 170H.
I 7KS. Thyroid
LRH Test
lnsulin-HGH
M e1opi rone�

PituitcJry

Tumor

who were felt to have adult-onset adrenogenital syn
drome. In all four patients there was a normal
response of FSH to LH-Releasing Hormone, but an
impaired LH response. Other testing was normal.
There were l wo other patients with organic
causes of secondary amenorrhea, one with
hypothyroidism and one with premature ovarian
failure. Test n::sults are as listed.
Secondary A 111enorrhea-Functional (Table 3 ).
Thirty patients had secondary amenorrhea which was
felt to be of functional etiology. Patients are divided
into diagnoses of anorexia nervosa (4 patients) and
"hypothalamic" causes (26 patients). This latter large
group is subdivided into patients who had rapid
weight loss or gain. stable weight. or had developed
amenorrhea after utilizing oral contraceptives. Skull
x-rays and physical examinations were negative ex
cept for that of weight change. and for four patients
who had galactorrhea.
All patients with anorexia nervosa and
hypoestrogenism had decreased gonadotropins.
Thyroid function was reduced slightly in two

TABLE 2
Secondarv0 Amenorrhea-Organic
( 16 Patients)
""Empty . .
CranioSella
pharyngioma

Androgen
Exct:ss

Shct!han·:-.

(2)

(2)

(2)

(4)

Acromegaly
(I)
Galactorrhea
(I)
+(3)
I (31
! (2 )

V. Fields ( 11

-

Hvpopit. (I)

Hirsutism (4)

+
I
I

+

-

Normal

HGHJ (II

170HJ (II

Normal

(4)

Pro lac-

tin j ( 11
FSH +2
LH +2
(Ii
+

!

-(I)

sl. I (II

-

+
+

Others:
Hypothyroid ( 1)-Galactorrhea: decreased estrogen. FSH. LH. thyroid :-.llldic�.
Other testing normal.
Prem..iture Ovarian Failure (I)-Decreased estrogen: elevated �SH and LH.
Other testing normal.
+ positive response. or normal test result.
- negative response. or reduced test result.

(Sec text for details.)

s� ndrvtllt!

I
I
170H It Ii
Thyroid J ( 11
-

(II
-

FSH Normal
LH I (4)
J 17KS (41
J Tcstos. (2)
j !'Trio! (21
FSH+
LH+
+
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TABLE 3
Secondary Amenorrhea-Functional
( 30 Patients)

Anorexia

"HYPOTHALAMIC CAUSES" (26)

Nervosa
(4)

Rapid wgt.
Loss(4)

Skull x-ray
P. Exam

-

-

Estrogen
FSH-LH

Diagnosis
(No.)

HGH. Pro-

Rapid wgt.
Gain(3)

Stable wgt.
( 15)

"Post Pill"
(4)

Galactorrhea
(.l)

Galactorrhea
(I)

Group Total
(26)
(4)

!

j(I)

Normal

(4)

(2)

J (7)

J

J (3)

J (2)

,l.j (2)

J (2)

sLJ (2)
J (7)

Thyroid sl.

Normal

Normal

Thyroid sl.

Prolactin

Thyroid! (3)

l (3)

1(1)

Prolactin I(I)
++(5)
sl. J (7)

lactin. 170H.
17KS. thyroid

l (2)

LRH Test

-(3)

-(3)

-(IJ

I +(5)
sl.J (6)

(IJ
sl.j(IJ

lnsulin-HGH

+

-(I)

+

+

+

(I)

Metopirone"

+

+

+

+

+

+

- (5)

+ positive response. or normal test result.
- negative response. or reduced test result.

patients. Three of the four patients failed lo respond
to LH-Releasing Hormone, but all patients had nor
mal responses lo insulin by growth hormone and to
Metopirone•.
The four patients with rapid weight loss. but not
anorexia nervosa. showed better estrogenization. but
low gonadotropins also. Similar poor responsiveness
to LH-Releasing Hormone was present.
A greater percentage of patients who had rapid
weight gain had normal estrogenization. baseline
gonadotropins. and normal LH-Releasing Hormone
response.
Patients with stable weight who were felt lo have
hypothalamic amenorrhea were basically normal in
estrogenization and baseline gonadotropins. All
patients had at least some response lo LH-Releasing
Hormone, and five had excessive responses. Patients
who developed amenorrhea after using oral con
traceptives were similar.
The 26 patients with hypothalamic amenorrhea,
as a group, were better estrogenized, had more nor
mal gonadotropins, and responded more normally or
excessively to LH-Releasing Hormone than did <he
patients with anorexia nervosa or patients with
organic causes of secondary amenorrhea.
0/igomenorrhea. Four patients had oligo
menorrhea, two with evidence of ovarian androgen
excess. Baseline estrogen, gonadotropins, and

other hormone testing were normal except for one
patient who was hypothyroid and two hirsute
patients in whom there were elevated 17-ketosteroids
and serum testosterone. All four patients had positive
responses to LH-Releasing Hormone. although in
two of these patients the response of LH was
borderline. All patients had normal responses to
lnsulin-HGH and Metopirone®.
Summary of Studies. In an attempt to summarize
these diagnostic studies, one can draw the following
conclusions from this group of 58 amenorrheic
women:
Skull x-rays are very useful, if positive.
Physical examination is useful when obvious
signs of endocrinopathy are present, including
acromegaly. hypopituitarism. galactorrhea. or signs
of androgen excess. Negative findings do not exclude
significant organic pathology, however. Findings
suggesting deficiency of a "target gland" (for
example, adrenal, thyroid) may be reflections of
pituitary-hypothalamic dysfunction rather than peri
pheral gland abnormality.
Patients with organic causes of amenorrhea are
more likely lo have clinical hypoestrogenism. and it
will lend lo be more severe than in patients with
"functional" or nonorganic causes. The exception is
anorexia nervosa. certainly a severe functional dis
order.
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FI UR E I
G
AMENORRHEA
OUTPATIENT EVALUATION

Thyroid
Adrenal

H,. Physical and Pelvic Exams
Maturation Index
Endometrial Biopsy
CBC. Urinalysis. Chem.
Skull ,-ray

170H. 17KS
FSH
Thyroid T,. T,
Progesterone;: Tcsl
Visual Fields

l l l

Andrugcn

1-a i lclJ

Ovary

SUSPECTED
HYPOPtTUlTARISM

Baseline serum FSH is of use in identifying
gonadal failure. or dysgenesis. when FSH is very
high. 1 n problems of androgen excess and functional
causes of primary amenorrhea. LH seems likely to be:
slightly elevated with FSH normal. Gonadotropins
are low in patients both with central organic causes
and with the more severe functional causes of this
problem.
Baseline measurements of growth hormone.
prolactin. 17-hydroxycorticoids and 17-ketosteroids.
and thyroid hormone all are of great use if ab
normal, but usually will require further evaluation.
Testing with LH-Releasing Hormone does
provide useful information. Patients with organic
causes of amenorrhea, other than gonadal failure or
androgen excess. were more likely to respond poorly
to LH-Releasing Hormone: however. a signiticant
proportion of these patients showed some response:
with regard to LH, or FSH, or both gonadotropins.
Patients with functional disorders more likely had
normal or excessive response to LH-Releasing Hor
mone while those classified as having more severe
functional disorders responded very poorly. Growth

hormone testing with insulin and Metopirone® test
ing were of relatively little diagnostic aid unless a
major organic etiology was present; an etiology
likely demonstrable on skull x-rays. clinical ex
amination. or in patients with more severe ab
normalities in baseline hormonal testing.
We would again emphasize that these are only
!rends in the results of diagnostic studies in patients
who present with amenorrhea. Larger group studies
are needed to evaluate the full statistical significance
of these data. We would also again emphasize the
need for a thoughtful. individualized. sequential
evaluation of each patient who presents.
Comment. To reach the goal of individualization
in the evaluation of the amenorrheic patient we
suggest several possibilities:
Figure I illustrates what we consider an ade
quate screening study for the amenorrheic patient
which usually can be done in the outpatient setting.
Based on these results. and the clinical tindings pres
ent. one can categorize problems under thyroid,
adrenal. ovarian androgen. or gonadal failure for
further studies which can usually be done in the out-

E

G
I' T

i

l l l

SUSPECTED HYPOPITUITARISM

INPATIENT STUDY

Baseline: FSH, LH. Prolactin. Estrogen. Growth Hormone
Metopirune" Test (")
Insulin-Induced Hypoglycemia Growth Hormone Test('')
LH-Releasing Hormone Test (A Y 24031)

l l l

"SUSPICIOUS"

"Fundiunal"

Follow-up
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the adequate endocrinologic work-up of the
amenorrheic patient.

E

1

l l l

.. SUSPICIOUS" HYPOPITUITARISl\1

2ND INPATIENT STUDY
If Prolactin-L-Dopa test: Chlorprom,.11inc tc:-.l. \Vatc.:r load
Pneumoenceph�1 logram
Carotid Arteriogram

THERAPY
(Medical. Surgical. Irradiation)

patient setting. Some patients will have suspected
hypopituitarism and require hospitalization for
further study.
Patients with the problem of suspected hypo
pituitarism should undergo further testing (Fig.
2) as evidenced by the preliminary studies. which
should at least include baseline hormonal testing and
testing with LH-Releasing Hormone. Growth hor
mone testing with insulin and/or Metopirone"
testing may be indicated. but this must be individ
ualized. Patients who are felt to have "functional"
disorders causing amenorrhea are begun on appro
priate therapy or follow-up, while patients who are
strongly suspected of hypopituitarism usually are
studied further.
Further studies (Fig. 3) include tests such as
prolactin kinetics. pneumoencephalogram. and
possibly arteriogram. If pituitary tumor. cranio
pharygioma. or other etiology of hypopituitarism is
found. then appropriate medical. surgical. or irradia
tional therapy is initiated.
In this fashion we have tried to present to you
the summation of data in 58 patients who presented
with amenorrhea. and the endocrinologic testing
results that have led to the <::stablishment of a
diagnosis. Again. it should be stressed that a
systematic. individualized work-up is mandatory for
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Amenorrhea Due to Defects 1n Steroid
Biosynthesis*
H. OLIVER WILLIAMSON. M.D. AND RAJESH S. MATHUR. PH.D.

Depar1ment of Obstetrics and Gynecology, Medical University of South Carolina,
Charleston. South Carolina

Amenorrhea as the first manifestation of a
steroid biosynthetic defect is rather unusual. The
common forms of congenital adrenal hyperplasia are
classic examples of steroid biosynthetic defects. Yet
in genotypic females. this disorder is usually evident
from birth because of virilization. Effective treatment
usually ensues and amenorrhea is only a problem
when control is inadequate. However. there are in
dividuals whose disorder will be manifest for the tirst
time in the postnatal or adult period. In addition.
multiple other steroid defects have now been clearly
delineated. Many of these individuals will have
amenorrhea, virilization. or sexual ambiguities as
part of the clinical picture. This paper will describe
some of the more clearly delineated steroidal bio
synthetic defects. Also, the clinical management or
patients with postnatal onset of 21-hydroxylase defi
ciency form of congenital adrenal hyperplasia will
be discussed.
Steroidogenesis. One can better appreciate the
biochemical defects and clinical manifestations of
these various steroid defects by having a rudimentary
knowledge of the basic steroid pathways involved. To
pinpoint the individual defects, it is helpful to recall
the numbering sequen..:e of the carbon atoms of the
steroid molecule as shown in Figure I. For the pur
poses of this discussion, one can consider cholesterol
as the basic substance from which steroids are de
rived. It is at the point of its conversion to pregnenolone
that tropic hormones have their effect; that is, ACTH
• Presented by Dr. Williamson al the 46th Annual McGuire
Lecture Series. December 5. 1974. al the Medical College or
Virginia. Richmond.
MCVQUARTERLY 11(\): 15-32, 1975

for the adrenal cortex, and the gonadotropins for the
gonads (Fig. 2). When circulating levels of glucocor
ticoids or sex steroids reach sufficient levels for
physiologic functions of the individual, the classic
negative feedback mechanisms become operative so
that further releasing hormones from the hypo
thalamus are held in abeyance, and the specific tropic
hormones from the pituitary are not released until
there is further need for additional hormones.
In the biosynthetic defects discussed here, the
steroid end products necessary for physiological
function are not formed in optimum amounts. This
triggers release of releasing factors from the
hypothalamus which in turn causes secretion of the
tropic hormones from the pituitary. Next, stimula
tion of the target glands (adrenal and/or gonads)
leads to excessive intermediate products being
elaborated up to the point of the defect. Clinical
manifestations of these disorders are due to a
deficiency of a normal end product, an excess of in
termediate substances with the possible peripheral
conversion to other hormones, or usually both. In
defects involving steps early in the biosynthetic
pathways, the adrenals and gonads are involved. Ab
normalities occurring later in the order of flow usual
ly involve only one gland or the other. Important sex
steroid precursors and weak androgens may be
formed by the adrenal and converted to more potent
androgens and even estrogens in certain of these dis
orders. Such conversions apparently occur in the liver
and skin and possibly other tissues. However, the
gonads do not form glucocorticoids.
Specific Defects. Brief descriptions of biosyn
thetic defects will be outlined starting at the more
15
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Cholesterol
Fig. I-Numbering sequence for the first 21 carbon atoms in
steroid nomenclature. Useful in locating biosynthetic steroid
defects described in this paper.

primitive, or early, stages of steroid biosynthesis
and proceeding to later-stage defects. Accordingly,
the order of presentation bears no relationship to
relative frequency or importance of these dis
orders.

C-20 block with /ipoid adrenal hyperplasia

(Desmolase deficiency CAH) (Fig. 3). Being unable
f
to convert cholesterol to pregnenolone, af ected in
dividuals lack life-sustaining steroids; hence the dis
order is fatal. The condition is of interest lo the
gynecologist in that it supports Jost's work regarding
virilization of the genital tracts. Being a primitive
(early) defect, it involves steroidogenesis in the
gonads as well as in the adrenals. The fetal testes are
unable to form adequate androgens to virilize the
genitalia fully, leading to genital ambiguity in genetic
males. This is in contradistinction to the findings in
the more common 21- and also 11-hydroxylase forms
of congenital adrenal hyperplasia where genetic
females are often born with ambiguous genitals.
Cholesterol accumulates in the adrenal of affected
individuals; hence the designation "lipoid." Theo
retically, the treatment would be the administra
tion of glucocorticoids and mineralocorticoids with
the addition of appropriate sex steroids at the time of
pubescence. Prader, Gurtner, and Siebenmann ( I, 2)

reported two patients with this disorder and collected
five additional cases. All seven died before the eighth
month of life with adrenal insufficiency even though
treatment with gluco- and mineralocorticoids had
been employed. Although other steroid abnormalities
may be present, it is probable that the main defect is
in the transformation of cholesterol to pregnenolone
(3). Early fatalities preclude this form of CAH in the
differential diagnosis of amenorrhea, though ultimately a mild form of the defect with survival might
be anticipated.

Three (3-hydroxysteroid dehydrogenase deficiency

(Fig. 4). Being unable to convert pregnenolone to
progesterone, these individuals present with many of
the features of the previously described desmolase
deficiency. Salt loss has been a prominent feature of
the adrenal insufficiency with the result that fatalities
are usual. Inadequate testosterone leads to am
biguous genitals in genetic males whereas mild
virilization of affected females has been attributed to
testosterone being formed from increased amounts
of dehydroepiandrosterone (DHA) and other pre
cursors. Since it is a primitive defect, gonadal
steroidogenesis is also affected. In Bongiovanni's
series (4), three females out of a total of six in
dividuals with this form of CAH were surviving. He
postulated a partial defect as did Kenny and his co
workers (5). The latter authors also showed in
creasing 3(3-hydroxysteroid dehydrogenase activity
with increasing age. Steroid excretion patterns in
these patients would suggest the development of
alternate pathways which allow for survival of some
infants. The presence of pregnenetetrol (with a
hydroxyl group at C 21) suggests the ability of 17hydroxylase and 21-hydroxylase to act on this
"primitive" molecule (6). This compound is not ex
creted in increased amounts in the usual 21hydroxylase deficiency (7). Since this enzyme also
plays an important part in the gonadal biosynthesis
of sex hormones (6), its absence would necessitate
substitutional sex-hormone therapy at pubescence.
Obviously sterility can be anticipated.
Seventeen cx-hydroxylase defect (Biglieri syn
drome) (8) (Fig. 5). This being a primitive block,
the gonads and adrenals are involved. Absence of
adequate sex steroids leads to hypogonadism and
elevated gonadotropins. The elevated levels of desoxy
corticosterone (DOC) and. corticosterone lead to
hypokalemic alkalosis and hypertension, thus turning
off the renin-angiotensin mechanism with resultant
low or absent aldoslerone. This defect is clinically ex-
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pressed in the genetic female by hypertension and the
absence of puberty. In addition to the elevated
gonadotropins, blood progesterone is high. In the
genetic male, ambiguous genitalia and absence of
puberty result from the inability to make either an
drogens or estrogens; hence it is a cause of male
pseudohermaphroditism (9). This syndrome in
genetic females is similar to the feminizing testicular
syndrome in the absence of secondary sex hair, bu!
differs in that breast development is absent and
hypertension is present. The treatment in females is
adequate substitutional therapy with glucocorticoids.
Preference is given to one without significant
mineralocorticoid activity; for example, prednisone.

Addition of sex steroids at pubescence is indicated,
but infertility can be expected. It would appear that
these patients could be monitored for effectiveness of
therapy by the measurement of plasma progesterone.

Simple uiri/izing congeniwl adrenal hyperplasia
(mild 21-hydroxylase defect) (Fig. 6). Being unable to

form optimal amounts of cortisol and corticosterone,
these individuals exhibit augmented ACTH produc
tion which leads to shunting towards the androgen
pathway and ultimate virilization. Aldosterone and
cortisol (hydrocortisone) are formed in suboptimal
amounts so tha< overt adrenal insufficiency may not
be necessarily manifes< (10, 11). The majority of fe
male patients will have exhibited considerable evi-
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dence of virilization and usually sexual ambiguity at
birth. leading to prompt diagnosis and treat111ent. In
the afTected male. however. the external genitalia
are nor111al and the diagnosis of CAH is therefore
less obvious. This doubtless accounts for the pre
do111inance of the disorder in females: that is. 111ales
may die of undiagnosed hypoadrenalis111.
Diagnosis and treatment depend largely on sup
pressibility of the hyperactive hypothalamic-pituitary
adrenal axis by exogenous administration or
11-hydroxylated glucocorticoids. Androgens are elt:
vated in plasma and urine. Estrogen excretion may
be elevated in these individuals ( 12. 13 ). Such es-

trogenic activity is not clinically manifest. Pre
sumably. the excessive androgens effectively over
ride the estrogenic activity. Most investigators have
held that urinary gonadotropins are suppressed by
the excessive androgens ( 13. 14). However. Stevens
and Goldzieher ( 15) found detectable and often adult
levels of gonadotropins in 4 of 5 children with
CAH and variable levels in adults. Steroid suppressive
therapy led to a fall of FSH in 3 of6 patients whereas
LH was unchanged in 5 and rose in 2. suggesting that
co111pensatory pituitary hyperactivity in CAH is not
limited to the pituitary adrenal mechanism but has
repercussions in gonadotropin regulation as well. In
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any event. once adequate suppressive therapy is in
stituted. postpubertal females rapidly feminize and
become ovulatory.
Diagnosis can be suspected on the basis or
baseline urinary 17-ketosteroids ( 17-KS). Normal
adult females ordinarily have values between 2 and 12
mg/24 hours. Patients with obesity. stress situations.
essential and familial hirsutism or Stein-Leventhal
syndro111e may have levels to 25 or even 30 mg/24
hours whereas patients with CAH usually will have
baseline values on the order or 50 111g/24 hours.
Patients with adrenal adenomas ordinarily will have
values of approximately 100 mg. and patients with
virilizing adrenal carcinomas will have values or 200

111g or up. The degradation 111etabolite of 17 hydroxy
progesterone ( I 70H-P). pregnanetriol, was found to
be elevated in the urine of these patients and has been
used for years to conf-irm the diagnosis and to
monitor therapy. Most laboratories report normal
values in adult females to be 4 mg or less per 24
hours. Patients with CAH have values from modestly
above 4 mg up to manyfold this level. The sup
pressibility of this steroid as well as 17-KS by 2 mg of
dexamethasone every 6 hours for two days proves the
ACTH dependence of the disorder and differentiates
it from the autonomous virilizing adenomas and car
cinomas ( 16). However. it appears that pregnanetriol
is not a primary intermediate in the formation of an-

0

"

CH,-C-S-CoA

,o�
CHOLESTER O L

I

3-/3-ol-deH

�

PREGNEN O LONE

17- 0H

- ,

I

,..

ro

HO(X)'

IS O M ERASE

1H,

C•O

OH

17- 0H-PREGNEN O LONE

OH A
( 17-KS}

.#
1

·Acetate"

1

21- 0H
�
Pre9nonediol

---+

•

0

h

PR O GESTER ONE"

fI

H
<i 3
C• O

OH

ALD OSTER ONE

H 2 0H ,?f

C H3
1
C• O

�

nelrlol
0
17- 0H -PR O GESTER ONE

H 2 0H

'

S H 2 0H

.o95 �.�

DESOXYC ORTICOSTER ONE
(D OC)
SH2 0H

°

.�? '
11-DESOXYC ORTISOL
(C O .SR}

OH

_,ffi
0�
TESTOSTERONE

CORTIC O STERONE
(C O . BK l
<iH2 0H
C•O
OH

0

C ORTIS OL
(C O . FK)

K

OH

,.o:SP
ESTRADI OL

glt11.:0L:orti1.:oid lormalion. Arnbiguou�
Fig. 4-Defect of J/3 ol-dehydrogenase-isomerase. Fatal due tu decreased mi1h.:raloconicoic.J and
due to peripheral convc.:1·
genitals in m..ilcs due 10 deficient androgen production to full) mas..:ulini1c in utcro. Partial virili1;.1tion ol fcmaks
sion of DHA to androgens.

WILLIAMSON AND MATHUR: DEFECTS IN STEROID BIOSYNTHESIS

20

,#

'(H2 0H

CH,-C-S-CoA
11
"Acetote
II

"'�
CHOLESTEROL

I

...

CH3

C•O

,,05°

ALOOSTERONE

CH20H

CHs
C

3-,8-ol-deH
IS=SE

0

•

C

O

•
a9t.
Pretnanediol

h

i

PROGESTERONE
P R E G N E N O LO N E
•i II IIIIII········"·�
ii ii
CH•
c,Hs
17-0H t
I ,
C O
C
• OH
•�
OH
�
o:9-?.
netriol
O
HO
NE
H-PROGESTERO
0
E
17-PREGNENOLON
17-0H

-+-

OH A
(17-KS)

•

O

ctsP

o
OESOXYCORTICOSTERONE
(DOC )
CH2 0H
1
c

·�oH

a9?
TH SR
O
h
11-0ESOXYCORTISOL
(CO.SR)

OH

_,ffi
0�
TESTOSTERONE

C H2 0H

'

/f

--

�

1

-H�rb

o�
CORTICOSTERONE
(CO. BK )
C, H2 0H

C•O
OH

o

�
CORTISOL
(CO. FK)

OH

,,oSP
ESTRAOIOL

Fig. 5-Seventeen <r-hydroxylase defect (Biglieri syndrome). Accumulation of mineralocorticoids leads to hypertension and deficiency of
sex steroids to absence of secondary sex characteristics in females and failurt: tu dt:vi:lup c.:,tcrnal gt:nitalia in rnaks.

drogens (17) suggesting that the major pathway is
through DHA and androstendione. Although 170H-P
has been known to be elevated in this disorder for
years (18). its measurement as a practical matter has
been of more recent vintage (19, 20). The bother and
inaccuracy of collection of 24-hour urine specimens
for steroid assays has led to the measurement or
plasma I 70H-P, progesterone, and testosterone in
diagnosing and monitoring these patients. Lippe and
co-workers point out multiple factors that may affect
serum steroid determinations (21 ): hence they suggest
that where virilization is a prominent feature in
amenorrheic women, long-term adrenal suppression
tests with measurement of several plasma steroids

(for example. I 70H-P and testosterone) be utilized.
Normal adult patients ordinarily have plasma I 70H-P
levels of up to 200-400 ng% whereas patients with
CAH and blocks of C-21 or C-11 hydroxylation will
have levels severalfold that amount when untreated
or if out of control (for example. 1-4 µg%) (19).
A subvariant of the mild 21-hydroxylase de
ficiency is that of the postnatal onset of the dis
order. Sporadic cases have been reported (22. 23. 24)
and described. It would appear that these individuals
have a milder form of the disorder which becomes
manifest only upon their being stressed.
Other subvariants of the 21-hydroxylation
deficiency include periodic fever in association with
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elevated plasma etiocholanolone (25) and "late"
sodium Joss (26). Hypoglycemia probably is not a
separate subvariant but a manifestation of hypo
adrenalism.
Severe 21-hydroxylase defect (salt-losing con
genital adrenal hyperplasia) (Fig. 7). This variant
of the 21-hydroxylase defect is more complete so
that a deficiency of mineralocorticoids including
aldosterone exists. Shunting to the androgenic
pathway is also present leading to virilization. The
defect. being of more profound degree, leads to even
higher ACTH levels than in the simple virilization
syndrome so that hyperpigmentation may ensue and
indeed has been used as a clinical sign in addition to

steroid assays in the monitoring of therapy.
Diagnosis is the same as with the mild form, but
treatment differs. In addition to suppressive therapy
with a glucocorticoid, a mineralocorticoid and often
salt supplementation are necessary. It has been
suggested that different 21-hydroxylation defects may
exist in the salt losers as opposed to the nonsalt losers
(27).
Eleven-hydroxylase deficiency (hypertensive con
genital adrenal hyperplasia) (Fig. 8). In addition to the
shunting along the androgenic metabolic pathway as
in the 21-hydroxylase defects, the mineralocorticoid,
DOC, accumulates, leading to salt retention and
hypertension. These patients also frequently pigment
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from the excessive ACTH activity. Clinically, these
patients present as the 11-hydroxylase patients except
for hypertension and salt retention. Diagnosis can
be suspected on the basis of hypertension. Biochemi
cal confirmation is by the finding of elevated levels of
tetrahydro-S (the degradation product of 11-desoxy
cortisol) in the urine. More specific radioimmuno
assays for DOC and 11-desoxycortisol may simplify
diagnosis in the future.
Late onset of this disorder has also been
reported (28, 29). Zachmann and co-workers exten
sively studied an infant girl with an 11-hydroxylase
deficiency who was normotensive and had normal
levels of DOC though compound S was excessively

high. This suggested to them a selected inhibition of
the 11/3-hydroxylation of I 7a-hydroxylated steroids
(30).
Eigh1een-hydroxy/ase dehydrogenase defec1 (Fig. 9).
Ulick (31) described this disorder accompanied by
low aldosterone resulting in low serum sodium. hi�h
potassium, dehydration, hypotension, high renin ac
tivity, and elevated levels of hydroxycorticosterone.
This disorder should not enter into the differential
diagnosis of amenorrhea and the virilizing congenital
adrenal hyperplasias.
Seven1ee11 /3-hydroxysferoid dehydrogenase de
feel (deficienf 1es1icu/ar J 7-ke1os1eroid reduc1ase ac
livity) (Fig. 10). Goebelsmann and co-workers (32)
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described a 46-year-old married phenotypic female
with clitoral enlargement, hirsutism, breast develop
ment, and a blind vaginal pouch. Chromosomal
karyotype was 46 XY. Abdominal testes were re
moved. Prior to operation, testosterone was at low
normal male levels, though considerably above female
levels. Urinary 17-KS were 33 mg/24 hours. The find
ing of androstenedione of 1.02 µg/ 100 ml (being ten
fold above normal male levels) suggested testicular
I 7JJ-hydroxysteroid dehydrogenase deficiency. More
recently, Givens and associates (33) described two
additional patients (sisters) with primary amenor
rhea. hirsutism. clitoral enlargement, 46 XY karyo
type. but lacking breast development. They, too,

found grossly elevated androstenedione levels along
with elevated urinary 17-KS and plasma estrone, but
subnormal amounts of testosterone and estradiol. In
vitro incubation of testicular tissue from their sec
ond case confirmed a partial defect in testicular 17KS reductase activity and documented increased 3JJ
hydroxysteroid dehydrogenase activity. They felt that
failure of breast development was probably due to
lower estrogen levels than in previously reported
cases. Accordingly. when one finds elevated 17-KS in
an amenorrheic individual, further delineation or
the defect by steroid biochemical assays seems
warranted. Indeed, such investigations may show the
Reifenstein syndrome as well as other forms of male

0
"
CHs·C-S-CoA
M
•Acetate

,#

yH2 0H

CHO LESTEROL
'

C=O

_.

'

C= O

OH

HO ,(:(:(
17- 0 H-PREGNENO LONE

'

,o�
DH A
( 17-KS)

0

h

I

h

C

OH

netrio�

=� OH

11-DESOXYC ORTISO L
(C O.SR)

l! H

C= O

a;n

O

CORTICOSTERONE
(C O .BK)
S H 2 0H
C= O

.o9?·"
CO RTIS O L
( C O. F•)

0

.....6.-�0.:.,
(17-KS)

DS°

�

DESOXYC ORTICOSTERONE
(DOC)
� H 2 0H

qH s
C=O

0
17-0H -PRO GESTERONE

i

=O

SH2 0H

'

CH2 0H /

o

PRO GESTERONE

'f

ALDOSTERONE

*

eH
3
�
�
Pre9nonediol
ISO MERASE

yHs

m

O

:·

,.DS°
PREGNENOLONE
17-0H

CH3

CH3

.o55

OH

_,ffi

0�
TESTOSTERO NE

OH

,o�
ESTRADIO L

Fig. 8-Eleven-hydroxylase defect. Virilization due lO shunting ol' adrenal precursors to androgenic pathway. Hypertension results lrom
accumulation of mineralocorticoids-principally desoxycorticostcronc.

WILLIAMSON AND MATHUR: DEFECTS IN STEROID BIOSYNTHESIS

24

,#

0
"
CH,-C-5-CoA

9H20H

"Acetate"

"�
CH O LESTER OL

I

t

,,oSD
_.

I

'f

�

IS O MERASE

qH ,

C• O

m

OH

HO(:()
17-0H-PREGNENO LONE

'

DH A
(17-KS)

C•O

3-/3-ol-de H

PREGNENOLONE

17- 0 H

CH s

CH s

C•O

�

ALDO STERO
�
CHz O �
,

21-0H

�
Pre9nonediol

�

.

0

OCC(
DES OXYCORTICOSTERONE
(DOC)
C H20H
1
C•
�OH

h

PROGESTER ONf

tI

q ,
C•O
H

OH

0
17-0H-PROGESTER ONE

�

netriol

i

-•�

1 l·DESOXYCORTIS OL
(CO.SR)

�

H

C,H20H

�rtS

OCC(
CORTICOSTER O NE
(CO. B K )
q HzOH
C•O

°

-- o� "
CORTISOL
(CO. FK)

0

--6·-��,\,
(17-KS)

OH

_,ffi
0�
TESTOSTERONE

OH

,,oSP
ESTRADIOL

Fig. 9-Dercct or 18-hydroxylase dehydrogenase. Aldostcronc deficit lead, tu dccrca,cd plasma sodium. high potassium. dehydration.
hypolension. and high renin activity. No direct gynecologic c:ndocrinop,llh) a:-.:-.cH.:iatiun.

pseudohermaphroditism to be due to this disorder of
steroid biosynthesis.
Stein-Leventhal syndrome (Fig. 11). Early
workers dealing with in vitro studies showed an ac
cumulation of DHA and testosterone in incubation
studies on ovarian tissue from patients with this syn
drome. These studies suggested a partial defect in
the aromatizing enzyme to convert testosterone
to estradiol as well as an inadequacy of 3/3-ol
dehydrogenase activity. However, such observations
were not interpreted to imply the uniform existence
of invariable, all-or-none enzyme defects in the
polycystic ovarian tissue (34). Accumulating evidence
would suggest, however. that the issue is much more

complex. Probably there are patients now classed
with this syndrome whose disease primarily resides in
the adrenal cortex. others who have primarily an
ovarian defect: but the majority have a defect in
hypothalamic function. Accordingly. it is felt that
there is no such neat demonstration of a consistent
biochemical defect as outlined in Figure 11 in spite of
early works suggesting such.
Case Presentations. Post-pubertal simple viriliza
tion. Patient M.S.H.. Duke Unit #5-59154 (Fig. 12).
A 17-year-old female was seen on referral November
I, I 961. with defeminization. Menarche was at 11
years with regular menses for two years. At age 13.
the patient had mumps and measles during a two-
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week period. Infrequent and scant menses. averaging
one per year followed. Acne and hirsutism steadily
progressed after age 11. Loss of scalp hair had
progressed for 5 months. Patient was said to be the
product of a normal term delivery, though she was
adopted. Pertinent laboratory findings are noted in
Table I. Two rest days intervened between the
ACTH. metapyrone, and dexamethasone tests. Sup
pressive therapy was started, and the patient had an
ovulatory spontaneous menstrual period 6 weeks
later proved by endometrial biopsy. She was mar
ried, and while on suppressive therapy. delivered
,pontaneously on January I, 196 7. under pudenda!
,lock anesthesia, a 5 lb. 8 oz. normal male infant

and on November 21, 1968, a 6 lb. 15 oz. normal
female infant by Dr. William A. Peters. Her pelvis
was normal by x-ray pelvimetry. During each de
livery, the patient was supported by parenteral
hydrocortisone, and her oral glucocorticoid was
doubled then gradually tapered to maintenance level
during the immediate puerperium. In that the
patient appeared so normal and was cycling spon
taneously, gl ucocorticoid therapy was discontinued
in September 1969. She has continued to have
cyclic menses without evidence of virilization. Dur
ing the past year. her urinary 17-KS were 13.7
mg/24 hrs on two occasions, and her 17-hydroxy
corticosteroids (I 70H-CS) 2.9 and 4.3 mg/24 hours.
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Co111111e111. Postnatal virilization of the female is
more commonly due to an autonomous tumor or in
gestion of hormones than due to the postnatal (ac
quired) form of congenital adrenal hyperplasia.
However. ready suppressibility of this patient's
greatly-elevated abnormal steroids bespeaks the
nature of her disorder. Since her onset occurred after
most. if not full. statural growth had been achieved.
she was not stunted. nor was her pelvic capacity com
promised. Accordingly. delivery was spontaneous.
Her children have been assessed for the possibility of
congenital adrenal hyperplasia. and this has been

ruled out. The chances of offspring having the dis
order are remote. since the prevalence of the gene for
the disorder is on the order of I in 128 for heter
ozygotes and I in 67.000 for the overt disease (35).
However. the frequency will be on the increase in that
affected individuals with proper treatment will no
longer be sterile (36). This patient is remarkable in
that she has remained apparently normal for a pro
tracted period of time off of therapy in spite of a
severe abnormality of steroidogenesis when first diag
nosed. Her 17-KS are now upper limits of normal and
her I 70H-CS are low bespeaking the fact that she
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probably is just minimally compensated. However.
she has undergone the stress of rearing two small chil
dren and moving to Europe without decompensating.
Accordingly. our original hypothesis or decompensa
tion due to psychologic stress of adolescence may bt:
questioned (37).
Postnatal simple virilization. Patient K.S.S.. Unit
# 61682 (Fig. 13). A 13-year-old white female was
seen January 18. 1963. because or "virilizing syn
drome." She was born prematurely. Development
was normal until age 4 when pubic and axillary hair
became apparent. Her 17-KS were elevated. and
glucocorticoid therapy was given elsewhere for two
years. but discontinued by the mother when
Cushingoid features developed. These rapidly dis
appeared. but were followed by progressive hir
sutism. One brother had prostatic hypertrophy
diagnosed at age 19.
Suppressive therapy was started January 23.
1963. and the patient was hospitalized elsewhere
April 3. 1963. with right lower quadrant abdominal
pain. Fifteen days later. menarche occurred and was
followed by regular menses and rapid budding or
breasts. Hirsutism gradually decreased. but her voice
remained unchanged. Significant laboratory data are
shown in Table I. Iliac crests were fused on the ab
dominal film. With her last menstrual period in
May 1967. and after an adequate trial of labor.
patient was delivered by cesarean on February 5.
1968. of a 5 lb. 7 oz. normal female. Opera-

Fig. 12-Paticnt M .S.H.. #F-59154. Normal r eminine contour and
cndocrint: mc.!asurements existed with comcdones and racial hir

,uti>rn. B.P. 120/70. Weight 61 kg.

TABLE I
Patient

M.S.H.

Age
17

Therapy
None
ACTH Gel 40 U IM
q. 12hrs. X 3days
Mctapyronc 500 mg
q. 4 hrs. X 2 days
Dexamethasone

27

Urinar� S11.:ruiJ ....

17-Kctogcnic

Prcgn..inetriol

82.8

I 1.-l

I). 7

9.7

16-l.7
77-l

.ll.O
-l 1.8

I )6.6
128.0

2-l.9
-13.2

-11.8

1.-l

9.8

2.9

H

0

3.6

0.5

17-KS

17-0H-CS

0.5 mg. q. 6 hrs. X 2 days
Dexamethasonc

2 mg. 4. 6 hrs. X 2 days
K.S.

13

71.3

None

40.1

Dexamethasone

I 8.3

107.8

Dexamethasonc

7.6

.ll.-l

Dexamcthasone

5. 7

0.5 mg q. 6 hrs. X 2 days
0.5 mg q. 6 hrs. X 2 days
2 mg. q. 6 hrs. X 2 days

2.7

11.6

1.-l
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Fig. 13-Paticnl K.S.S .. # 6168�. ShO\\:,, :-.tunlcd grtl\\th. L.11..:ial hir
sutism. and android c:-.cu1chcon. Chc:,,t \\a:,, :,,havcd prior to
photograph� i'vl usck hypcrtroph� \\ <h pn::-.cnt and brca:-.t develop
ment ab:-.cnt. Voice \\a:,, baritone. B.P. 150190. \\ 1:ight 55.5 !..g.
Hcighl 152 cm. Sr,an 151 cm. LO\\Cr :-.cgmcnt 76 cm.

tion was necessary due to a moderately con
tracted pelvis of somewhat android configuration.
The patient has been maintained on prednisone 5
mg at bedtime. She continues to cycle normally. Her
plasma I 70H-P of 216 ngo/,. plasma progesterone
1.4 µg0!c in luteal phase with plasma estradiol 20.3
ng%. suggest ovulation. However, her plasma tes
tosterone persisted in the range from 80 to 120
ng% bespeaking continuing excessive testosterone
production. Accordingly. an additional 2.5 mg of
prednisone is being added in the morning.
Co111111e111. Failure to continue glucocorticoid
therapy as prescribed by her physician led to
premature closure of this patient's epiphyses and ul-

timate stunting from excessive sex steroids. In turn,
this probably necessitated delivery by cesarean
because of cephalo-pelvic disproportion. In the past,
some patients with adrenal hyperplasia who could
not tolerate steroid therapy have been subjected to
adrenalectomy. However, such surgical therapy is no
longer warranted, for proper monitoring should be
achievable so that the disease can be brought under
control without significant side effects from the
medication. Hayek and associates have suggested the
single dose of a long-acting suppressive agent at mid
night for therapy of this disorder with good results:
hence simplifying therapy (38). Such therapy is
appealing and rational. However. one must use a fair
ly long-acting steroid: therefore. oral hydrocortisone,
the naturally occurring hormone that is missing, can
not be utilized. Problems persist in such patients as
this who have their sleep-wake patterns altered by
work habits (she is a telephone operator working
swing shifts). This may account for the need for an ad
ditional a.111. dose. Reversibility of some signs of
virilization occur (the patient has lost much body
hair. though some facial shaving is still necessary).
Rapid feminization as shown by breast development
and ovulatory menses is to be expected once adequate
therapy is instituted. Her hospitalizaiion was for
suspected appendicitis. but the pain was apparently
mittelschmerz. since she had her menarche two weeks
later. Clitoromegaly and deep voice have persisted in
this patient. since such changes. once they occur. do
not reverse. Contraception in this patient. as well as
in the first, is by intrauterine device. Estrogen
containing oral contraceptives should be avoided
in as much as they confound steroid monitoring of
such patients by altering steroid binding proteins.
This patient was found to be hypertensive when
initially seen. raising the question of a possible 11hydroxylase block. However. measurement of
tetrohydro-S showed no significant amounts of this in
the urine. Prolonged hypertension following cessa
tion of desoxycorticosterone therapy in CAH has
been reported (39): however. we feel that this is
highly unlikely in this patient. since initial therapy
had been discontinued for almost a decade before
she was found hypertensive.
Pa1ie111 L. 0. T., Uni/ # 235684-5. A 38-year-old
nulliparous obstetrical nurse was seen on referral
because of inadequate control of adrenal hyperplasia
while laking divided doses during the day. Some
evidence of virilization probably was present at birth
(clitoromegaly). though hirsutism did not become
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manifest until after age 5. In 1954, the patient
elsewhere underwent vaginoplasty, abdominal ex
ploration, and clitoridectomy with the findings or
follicular cyst of the ovary with occasional ova and a
hypertrophic clitoris (5 cm.). The adrenals were
thought normal to palpation. The patient was em
pirically treated with Premarin® and thyroid and
had withdrawal bleeding. All therapy was discon
tinued in 1964, and she had spontaneous regular
menses for one year with flow lasting 3-5 days and on
occasion had associated cramping. Her baseline 17KS were 51 mg. rising to 109 with ACTH and sup
pressing to 13.4 mg. with Decadron®. She was dis
charged on 25 mg. cortisone per day and was later
changed to prednisone. However, she was seen on
referral, and her urinary pregnanetriol was 31.5 mg/
24 hrs. She was shaving twice daily. The patient was
working swing shifts as a registered nurse. She was
advised to take 5 mg. prednisone before going to bed
and 2.5 on arising and an additional 2.5 mg during
the day if necessary. Since institution of this therapy.
her plasma testosterone has ranged from 16 to 28
ng% with concomitant loss of chest and arm hair.
though facial shaving is still needed. Her plasma
estradiol has been between 2 and 43 ng%, though
she has remained anovulatory while cycling. as
shown by plasma progesterones repeatedly less than
400 ng%. Her I 70H-P has ranged from 118 to
496 ng%.
Comment. Patients working swing shifts can ex
perience considerable difficulty in controlling their
excessive androgen production since the ACTH surge
may come at a time when they are not receiving their
larger dose of suppressive steroid. Also, changing
shifts alter diurnal variation and may in itself be a
stressful situation causing further decompensation. If
even suppression is not obtained by giving a dose
prior to anticipated ACTH surge, consideration of
longer-acting injectable therapy such as utilized in in
fants may be considered. Neither this patient, nor our
patient undergoing cesarean, had evidence of
classical Stein-Leventhal type ovaries, although CAH
has been noted associated with polycystic ovaries
(40). The thickened capsules in such patients have
been attributed to excessive androgens.
Patient P.B., Unit # 233484-2. A 23-year-old
gravida II, para I, abortus O had menarche at age 12
and cyclic menses until age 16 when she started skip
ping menses. At age 17, she had ovarian wedge resec
tions elsewhere with diagnosis of Stein-Leventhal
syndrome. However, menses did not resume. She was
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seen by another physician who treated her with pred
nisone. Menses then resumed, and the patient spon
taneously achieved a pregnancy only to have mid
trimester loss with prolapsed cord, intrapartum
death, and delivery by cesarean. On physical exami
nation, the patient had considerable facial hirsutism,
modest clitoromegaly, but normal size ovaries.
The patient was again studied off therapy with ele
vated l 70H-P of 4.4 µg%. Her plasma progesterone
was 132 ng%. With adequate suppression, plasma
progesterone rose to 1.7 µg% (ovulatory level) and
I 70H-P fell to 160 ng% (normal). The patient spon
taneously resumed menses and became pregnant with
last menstrual period November 11, 1974. On Janu
ary 8. 1975. continuing the same dose of 5 mg
prednisone at bedtime, her plasma testosterone was
80 and plasma I70H-P 137 ng%, and her plasma
progesterone was greater than 1.6 µg%.
Comment. Patients with congenital adrenal
hyperplasia being adequately treated will be unable
to have plasma or urinary estriols as an index of fetal
well-being in as much as these steroids cross the
placental barrier and suppress fetal-adrenal ac
tivity-a most important source of precursors for
pregnancy estriol. Differential suppression tests
should be able to delineate patients with primarily
ovarian disorders as opposed to those with primarily
adrenal disorders and prevent unnecessary wedge
resections in the future.
Patient L.H.. Unit # 235525-8. A 27-year-old
patient was seen in consultation because she had
developed Cushingoid features as a result of being on
prednisone for persistent amenorrhea. Menarche was
at age 12 with an average of one cycle per year until
age 18 when she was placed on oral contraceptives
with regular withdrawal bleeding for three years.
Upon discontinuance, the patient remained amenor
rheic for one year when she was seen by a gyne
cologist and had bilateral wedge resection of ovaries.
She remained amenorrheic for another year except
for scant spotting on rare occasion. The patient
was admitted to another university center and under
went dexamethasone suppression test with 17-KS,
suppressing from 21 mg/24 hours to 6 mg on the
first day of high-dose dexamethasone. She also had
adrenal and ovarian vein catheterization, showing
adrenal venous plasma testosterones quite elevated
with some elevation of ovarian and peripheral
values. She was placed on prednisone 10 mg every
other day with spontaneous menses occurring ap
proximately every 6-7 weeks. She then relapsed into
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amenorrhea. Medication was discontinued for retest
ing. and after one month off of therapy. her
plasma I70H-P was 1.8 µgo/o (approximately five
to tenfold the normal values) with plasma testoster
one 79 ng% (upper limits of normal for adult
females in our laboratory are 60 ng%). plasma
cortisol 10 µgo/o at 8 a.m.. plasma estradiol 24.1
ng% (normal proliferative phase value), plasma
progesterone 94.5 ng% (anovulatory value). On
suppressive therapy. I 70H-P fell to 165 ng%, tes
tosterone was 71 ng%. and plasma estradiol re
mained at 22.9 ng% with progesterone 78 ng%.
Stimulation with Clomid®. escalating doses to a
maximum of 150 mg/day times five days. indicates
the patient remains anovulatory with progesterone
50.5 ng%. plasma estradiol 24 ng%. while 170H-P
has remained 112 to 216 ng% during the time she
is being maintained on p.m. suppressive prednisone.
Commenl. This patient with a mild form of 21hydroxylation defect with first manifestations in post
natal period did not achieve smooth suppression with
alternate-day therapy. Even though nighttime
therapy has brought about normalization of I 70H-P
and near normal values of plasma testosterone. she
remains anovulatory and unresponsive to Clomid""
at this time. In this patient, the elevation of 170H-P
in the plasma out of proportion to the progesterone
would indicate that her primary pathway to I 70H-P
is through 17-hydroxy-pregnenolone rather than
through progesterone. Also. findings would suggest
that even though near-optimal biochemical control of
the disorder can be achieved. fertility does not
automatically ensue. She probably needs further sup
pressive therapy. If optimum control is then achieved
as shown by normal plasma testosterone. I 70H-P.
and urinary 17-KS. then a search for other causes or
amenorrhea are warranted, for they can be subject to
such disorders as hypothalamic amenorrhea.
Patieni J. L., Unit # 161059. An I I-year-old
patient was seen in consultation after she had seen a
group movie at school on sexual development in
which a photograph of abnormal external genitalia
was shown. She persisted in telling her teacher that
she had such abnormal genitalia. Although "show
and tell" in its fullest sense did not occur, this ex
perience led to her being referred where the disorder
was well characterized. She is now on suppressive
therapy.
Comment. Clitoromegaly of this degree, had it
been present at birth, surely would have been
recognized, though possibly some physicians may

attempt to downplay its importance. However, the
clinical course of this patient, that is, the onset of
hirsutism and facial acne just prior to her evalua
tion. would suggest postnatal onset of her disorder.
Patient C. G., Unit # 172230-/. A 20-year-old
patient had onset of virilization at age 11, and the
diagnosis of congenital adrenal hyperplasia was made
at a medical university well known for its large series
of congenital adrenal hyperplasia patients. Initial
attempts to control her here by continuing cortisone
acetate which had been instituted elsewhere failed,
and she was switched to prednisone in 1970. taking
2.5 mg every eight hours. However, when seen in
February. 1974, her 170H-P was greater than 1.4
µgo/o. and her plasma progesterone greater than 1.6
µgo/o. with plasma testosterone 72 ng%. She was
anovulatory as shown by endometrial biopsy and
basal body temperature charts. Five mg. of pred
nisone at bedtime still failed to achieve suppression
with plasma I 70H-P of 3.7 µgo/o, therefore, pred
nisone has been increased to 7 .5 mg/day while sterili
ty investigation is being pursued.
Discussion. Differential diagnosis of congenital
adrenal hyperplasia includes disorders of adrenal and
gonadal origin. Rarely are such entities as Morgagni
Stewart-Morel syndrome or Achard-Thiers syn
drome of any importance in the differential diagnosis.
if indeed they represent true syndromes.
Cushing·s syndrome is readily differentiated by
overnight dexamethasone suppression test in most
patients and by baseline values of glucocorticoids.
Rarely is virilization of the degree seen with CAH
present in patients with Cushing's syndrome. Ex
ogenous administration of virilizing hormones can
present a problem particularly when the patient does
not know what she has received. Anabolic steroids
have been given in wasting diseases, osteoporosis.
and to improve libido. The differentiation of ovarian
hyperandrogenic syndromes including Stein
Leventhal syndrome can generally be made on the
basis of differential suppression tests employing
glucocorticoids to suppress the adrenal component
and combination estrogen-progestogen preparation
such as Enovid"" E for the ovarian component (41.
42). True hermaphroditism usually is not much of a
problem since prepubescent hirsutism is not usually
evident even though ambiguous genitalia may exist.
Steroid assays readily differentiate the conditions.
Occasionally, patients with gonadal dysgenesis with a
Y stem line (usually) may present with signs or hir
sutism and clitoromegaly. This has been particularly
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true of patients with gonadoblastomas or Teter's
gonocytomas III and IV. Again, steroid assays readi
ly differentiate the condition. In patients with viriliz
ing ovarian tumors such as an arrhenoblastoma,
elevated androgens will not suppress with exogenous
administration of glucocorticoids. Further, their
urinary 17-KS are generally not of the magnitude or
those seen with CAH.
Summary. Enzymatic defects of adrenal and
gonadal steroidogenesis have been described, many
of which lead to amenorrhea and sexual ambiguity.
Seven patients with congenital adrenal hyperplasia
are presented who were first diagnosed at times far
removed from the neonatal period. One such patient
had dramatic onset of hirsutism, amenorrhea, and
profound elevation of androgens. After suppression.
she achieved two pregnancies, delivered. and subse
quently has gone off therapy and continues to have
cyclic menses in spite of borderline steroid values.
The usefulness of a single nighttime long-acting
glucocorticoid in achieving smooth suppression in
patients with adrenal hyperplasia appears rational
and is meeting with success. Diagnosis and monitor
ing of therapy of such patients has been facilitated
by the availability of immunoassays for 170H
progesterone, and testosterone in lieu of urinary 17KS, and urinary and plasma pregnanetriol assays.
Authors' note: Since preparation of this presenta

tion, Sa reductase deficiency has been described in
association with male pseudohermaphroditism.
(Walsh et al, Familial incomplete male pseudo
hermaphroditism, type 2, decreased dihydrotestoster
one formation in pseudovaginal perineoscrotal hy
pospadias, N Engl J Med 291:944-949, 1974).
Acknowledgmenr: The authors wish to thank Dr.
Richard Horton for the testosterone antibody, Dr.
Walter Wiest for the progesterone antibody. and Dr.
V. B. Mahesh for the estradiol antibody.
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Treatment of Amenorrhea: When Pregnancy Is
and Is Not Desired*
JOHN A. BOARD. M.D.
Professor of Obstelrics and Gynecology. Medical College of Virginia.
Hea/1h Sciences Division of Virginia Co1111nonwea/1h University. Richmond, Virginia

We have had three discussions this afternoon
concerning amenorrhea. and most of these have dealt
with the diagnosis of causative conditions. I am going
to discuss the treatment of these women.
Whether or not the woman wishes to conceive in
the immediate future determines the plan of treat
ment in most cases. If conception is desired. I believe
it should not be immediately assumed that the
amenorrhea is the sole cause of the infertility. I would
check patency of fallopian tubes and adequacy of the
husband's sperm production before treating for con
ception. Regardless of the plans for pregnancy.
however. it should be determined whether the woman
is merely not ovulating with adequate endogenous
ovarian estrogen production or whether the ovula
tory failure is associated with lack of estrogen as well.
The former might occur if pituitary gonadotropins
were reduced and/or the preovulatory LH surge were
absent. The latter condition may be due to failure
of production of pituitary gonadotropins or to meno
pause with elevated levels of pituitary gonadotropins.
Several brief case reports of women with
amenorrhea will follow. In some of these. there will
be organic disease of the extragenital endocrine
glands such as the thyroid gland, or the adrenal
gland, or the pituitary gland. In others, there will be
no identifiable extragenital endocrine disease: then
the treatment would vary depending on whether or
not the woman wishes to become pregnant.
Case I. This patient was a 35-year-old gravida I.
• This is an edited transcription of a lecture presented by Dr.
Board at the 46th Annual McGuire Lecture Series. December \
1974. at the Medical College of Virginia. Richmond.
MCV QUARTERLY 11(1) 33-36, 1975

para I. aborta O who was seen after having amenor
rhea for six months. She had noticed tachycardia,
sweats. and weight loss. The radioactive iodine
uptake was 80% in 24 hours: this is much higher than
normal for this laboratory. A diagnosis of hyper
thyroidism was made. The patient was treated with
radioactive iodine and had resumption of regular
menses after the second course of treatment. She is
not presently trying to become pregnant.
In preparing for this talk. I was looking for in
stances of thyroid disease that caused amenorrhea,
and I couldn't find any where hypothyroidism was
the etiologic factor. I am as aware as you all are of the
thousands of women who have taken thyroid medica
tion as treatment for amenorrhea. but in the patients·
charts to which I had access. I could not find one
where this was the real etiologic factor. I did find
the following case of hyperthyroidism.
Case 2. This was a 30-year-old gravida 11, para I
who had had amenorrhea for two years after a spon
taneous abortion. She had moderate hirsutism. but
no other virilizing signs. An endometrial biopsy
showed "resting endometrium," that is. proliferative
glands without mitotic activity. Thyroid studies were
normal. and two urinary 17-ketosteroid deter
minations were moderately elevated: 16.1 and 18.1
mg/24 hours. It was decided that this was a case of
adrenal androgenic hyperfunction. The patient was
initially treated with dexamethasone 2 mg three
times a day for 2 days. followed by 0.75 mg/day
for maintenance. Ultimately. this was reduced to
0.5 mg/day. Under this treatment, the urinary 17ketosteroids fell to 2. 7 mg/24 hours. Ovulatory
cycles began and conception occurred.
33
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Case 3. This was a 26-year-old gravida 11. para 2
who was seen because or amenorrhea and galac
torrhea since her last delivery two years earlier. This
patient had been worked up about a year pre
viously elsewhere and had had normal skull x-rays.
normal visual fields. and normal EEG. The skull
x-rays were repeated: this time a destructive lesion
of the sella was seen. and the visual tields had a
bilateral defect. A transsphenoidal removal or pru
lactin-producing pituitary adenoma was done leaving
the remainder of the pituitary gland. Following this.
spontaneous menses have returned and they are
ovulatory. The visual fields have also returned tu
normal.
The first three cases dealt with patients who had
organic diseases of extragenital endocrine glands.
The remaining four cases have nu identiliable ex
lragenital endocrine disease.
Case 4. This was a 20-year-uld gravida O "hose
menses began at age 13 and had occurred every 35
days lasting 7 days until two years earlier when
amenorrhea had begun. coinciding with the lirst year
of college. She had a history or having received
thyroid medication in the past although she had
received none for the preceding year. The l"ree T, was
1.5 mg%. a normal value. and the maturation index
was 0/65/35. Oral medroxyprogesterone was admin
istered. and the patient had withdrawal bleeding
after this. An extensive investigation was not dune.
but the medroxyprogesterone medication was con
tinued for 3 months. After this. spontaneous
cycles returned.
Patients who have endogenous estrogen can
usually be treated with only a pure progestin given at
monthly intervals. It is unlikely that they have
anything seriously wrong with their hypothalamic
pituitary axis. When given an exogenous progestin at
monthly intervals (we usually give medroxyproges
terone for 5 days beginning al cycle day 22).
monthly bleeding episodes usually result. Some
women who do not want to menstruate 13 times
a year will be given the medication two 10 rour
limes a year. I do not think it is good for endu
metrium to be continuously stimulated by estrogen.
whether it is endogenous or exogenous. because ur
the possibility of endometrial hyperplasia. and I
think that even if the woman is not enthusiastic
about menstruating, she should be given this medi
cation at least several times a year.
Case 5. This was an 18-year-old gravida O who
had onset or menses at age 10 and who had had
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menses every 31 days lasting 5 days until she
entered college. Prior to this, she had experienced
amenorrhea in the summer when she had gone
away to camp. but the amenorrhea had ceased
when she returned home. She had very slight
hirsutism. and there was no withdrawal bleeding
after medroxyprogesterone. The serum FSH and LH
were normal. Tests of thyroid function. skull x-rays.
and urinary 17-ketosteroids were normal. The patient
was treated with cyclic estrogens and progestins
(conjugated estrogens 1.25 mg daily for 21 days
with medroxyprogesterone 10 mg daily added on
treatment days 17-21).
The failure of withdrawal bleeding after
medruxyprogesterone alone in a patient who does
have "·ithdrawal bleeding after estrogen-priming be
fore a prugestin is given indicates lack of endo
genous estrogen production. The group or patients
without endogenous estrogen includes cases where
the defect is ovarian (such as agenesis. castration.
or premature menopause) as well as cases or pitui
tary failure (such as that secondary to defective
releasing factors. ablation by surgery or radiation.
and diseases such as Sheehan·s syndrome). If this
syndrome appears at a time when it is appropriate
for a woman to stop menstruating. as would be the
case if she were in her mid-40's. I don't think the
condition necessarily needs to be treated. Certainly
when it occurs in an 18-year-old girl. as this did.
I believe that it is reasonable to treat with estro
gen plus a progestin. This will result in regular
episodes of withdrawal bleeding.
Case 6. This was a 27-year-old gravida I. para I
who had become pregnant the first time without
dilliculty. but who had had amenorrhea for six years.
She desired pregnancy. She weighed 208 pounds. had
mild facial hirsutism. and normal adnexa. Urinary
17-ketosteroids were 4.4 mg/24 hours. a normal
value. The maturation index was 0/86/14: a Rubin's
test had shown tubal patency. and a postcoital test
had shown abundant sperm. After medroxyproges
lerone-induced withdrawal bleeding. this patient
was given clomiphene 50 mg daily for 5 days. and
she promptly became pregnant in the first month
of treatment.
When clomiphene is used. the pregnancy rate
will he around 30%. The incidence or ovulation is
much greater than 30%. but every patient who shows
evidence or ovulation does nut always become preg
nant. This may be due to the fact that we think the
p..:rsun is ovulating when she really is nut. All of our
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indices for detection of ovulation are based on the
effects of progesterone, because we know that in nor
mal women progesterone is present and exerts its
effect primarily after ovulation, and we assume that
this also happens in abnormal states. I am not ab
solutely sure that this is so, but I have no valid proof
that it is not. Ovulation apparently is induced. or at
least progesterone is produced, in about 70% of the
women receiving clomiphene, but pregnancy occurs
only in about 30%.
Sometimes couples will want to know when is
the best time for exposure after clomiphene to
achieve a pregnancy. It is my practice to tell the
patients to begin having regular intercourse about
four days after the last tablet and to continue this un
til the basal temperature has been up for three days.
Clomiphene is not without side effects. Ovarian
enlargement may occur in about 14% of patients. and
sometimes the ovaries become quite large. but the
problem is much less than with the agent that will be
dis�ssed shortly. Hot flashes are the common com
plaint that patients report. If patients are reassured
about this and told that they are not menopausal. it
does not seem to be a troublesome effect. The in
stance of multiple pregnancy is increased tenfold.
Under normal circumstances. the incidence of multi
ple pregnancy is around I in 80: with clomiphene it
will rise to around I in IO or I in 12. Blurring of vi
sion may occur in around I% of patients. and when
this occurs. it is an indication to discontinue the
medication. Spontaneous abortion occurs at a higher
rate than would be expected.
Case 7. This was a 29-year-old gravida I. para I.
aborta O who desired pregnancy and who had had
amenorrhea for nine months when she was first seen.
She had been on oral contraceptive medication prior
to her first pregnancy: this had been discontinued.
and she had conceived promptly without difficulty.
After that pregnancy, she took combination oral con
traceptive tablets for several years. Her other work
up had indicated that her thyroid function was nor
mal, that the blood FSH and LH were normal. and
that 17-ketosteroids were also normal. Tubal patency
and sperm production were adequate. Attempts to in
duce ovulation with clomiphene began with a low
dose of 50 mg daily for 5 days. This was raised
gradually to 200 mg/day for 5 days, with chorionic
gonadotropin added after this. This was not
successful; then treatment with menopausal-chori
onic gonadotropin was given according to the
outline in Table I.
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TABLE I
Outline of Gonadotropin Rx
lb Day
I
.1
4

8

9
10
II
12
13

Cervical
Mucus

0
0
0
I+
I+
2+
2+

3+

H
4+

Plasma

Estradiol

Rx

1.14 pg/ml
179 pg/ml
2.17 pg/ml
332 pg/1111
478 pg/ml
938 pg/ml

HMG 75-75 u.
HMG 150-150u.
HMG 150-150u.
HMG 150-150u.
HMG 150-150u.
HMG 225-225u.
HMG 300-300u.
HMG 300-300u.
HMG 300-300u.
HMG 10.000u.

BBT down
Sustained rise in BBT began. followed by menses.

1n such cases. one may get response to
menopausal plus chorionic gonadotropin. The in
stance of pregnancy with this treatment is around
25%. This treatment is also associated with side
effects. One has to be very careful in giving it.
Ovarian enlargement may occur in up to 20% of the
cases. and in extreme instances may be associated
with acites and even plural effusions. The cysts
may rupture. and there may be hemoperitoneum.
The severe hyperstimulation syndrome is found to
be associated with abdominal distention and
hemoconcentration (because so much of the body's
total fluid volume has gone into the abdominal
cavity). The treatment is bedrest. intravenous fluids
with close monitoring of electrolytes. and avoid
ance of pelvic examinations. This can become
serious. can lead to thrombosis. and there have been
several deaths. The instance of multiple pregnancy
with menopausal-chorionic gonadotropin treatment
is 20-37%. and the instance of abortion is around
28%: an incidence greater than would be expected
with normal spontaneous ovulation. In one series, it
was found that three-fourths of the multiple pregnan
cies were twins. and one-fourth of the multiple preg
nancies were three or more.
There are several problems in treating women
with gonadotropins. One wants to give enough
medication to induce ovulation, but not so much that
the hyperstimulation syndrome is produced. In
this particular patient, the menopausal gonadotropin
dosage was gradually increased until day IO when
good cervical mucus was seen, indicating that,
more than likely, enough medication had been.

36
given. Laboratory tests of estrogen production
were done to determine that too much had not
been given. In many institutions. the determination is
of urinary estrogen. but at the Medical College or
Virginia there is a technique whereby plasma es
tradiol can be measured in about six hours. The
patients have blood drawn in the morning and return
at 4:00 p.m .. at which time the laboratory data is
available. The aim is to reach a level or between 500
and IOOO pg/ml of estradiol. If the level stays un
der IOOO pg/1111. the incidence of hyperstirnulation
syndrome is much less than if the level is higher.
If this patient had been given another day or treat
ment. a situation might have been created where
hyperstimulation would have occurred. The patient
did not become pregnant. although evidence for
ovulation was obtained from basal temperature
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charts. I want to emphasize this because I think this is
a way a physician can get in trouble. One can decide
when he has given enough estrogen by the effect on
cervical mucus. but one cannot tell when he has given
too much. If estradio I levels are too high, one would
not give chorionic gonadotropin, stop the treatment,
and try again in a month or so, giving less medi
cation. I think to avoid serious complications in
treating a nonlethal condition. there has to be some
way of assessing the estrogen production from the
stimulated ovaries.
I have tried to illustrate the treatment for
amenorrhea of different causes and to emphasize the
fact that the treatment is different when the woman
wishes or does not wish to become pregnant. I have
also pointed out some of the hazards of the various
methods of treatment of this condition.

Patient Factors Limiting Success of
Cancer Detection*
DEAN R. GOPLERUD, M.D.
Associate Professor of Obstetrics and Gynecology, Medical College of
Virginia. Health Sciences Division of Virginia Commonwealth University, Richmond. Virginia

The American College of Obstetricians and
Gynecologists has established as one of' its goals for
the next decade the reduction of mortality from
breast and pelvic cancer by 50% (I). Radiation
therapy and surgery are the main modalities of treat
ment for most genital cancers. These modalities have
advanced to the level of diminishing returns. lm
munotherapy is in its infancy, and chemotherapy is
presently used mainly for palliation and for
prolongation of life except for a few malignancies,
choriocarcinoma being the classic example.
Barring a monumental breakthrough. it appears
that any major advance in improving mortality
statistics will be the result of early cancer detection.
Cancer detection involves many factors. but basic
units in the scheme include the patient, the physician
or his representative, and the facility in which detec
tion procedures are carried out. It is safe to assume
that most people do not need to be convinced that
early cancer detection is a desirable goal. Many facili
ties exist such as physicians' offices, hospital facili
ties, and public clinics, all of which can figure promi
nently in cancer detection. One of the major unful
filled objectives of cancer detection programs is the
inclusion of all eligible patients. This requires motiva
tion of patients in such a manner that they will seek
out and utilize the available cancer detection facilities.
The Papanicolaou smear and routine pelvic ex
amination have been shown repeatedly to be simple,
reliable, painless, and widely available. Yet, only an
estimated 50% of the eligible women in our communi• Presented by Dr. Goplerud al the 46th Annual McGuire
Lecture Series, December 6. 1974, al the Medical College ol'
Virginia. Richmond.
MCV QUARTERLY 11( I): 37-40, 1975

ty have ever had a Pap smear. There is an even higher
proportion of post-menopausal women who have
never had a Pap smear. It is precisely from this pop
ulation that we see patients who have far-advanced
tumors of the cervix at the time of their first admis
sion.
What are the reasons for this apparent dis
crepancy between the availability of the means for
early detection and the lack of utilization? This is the
problem I would like to explore and make some
suggestions for improvement.
If women are to participate in programs for early
detection of cancer, there are several steps that must
be taken. First, they must know about the program
and its value. The dissemination of cancer informa
tion is a worthwhile endeavor, but education of the
patient takes place in different ways. Certainly the
cancer education program of the American Cancer
Society, our public health agencies, our medical
societies, and universities should not be abandoned,
but to a great extent we are preaching to the "already
converted." The women's clubs and PTA groups that
often sponsor education programs by the local
Cancer Society are composed largely of women who
are already convinced of the value of early cancer
detection. Most gynecologists in private practice are
very concientious about performing regular pelvic
examinations including Pap smears on their patients.
Commendable as this may be, the number of positive
smears obtained in this manner is not great, and oc
f
casionally one may wonder if it is worth the ef ort
and expense to do smears once or twice a year on
women who have had several previously negative ex
aminations. Asymptomatic women who come regu37
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larly to the private gynecologist's office are basically
a low-risk group for the development of cervical
cancer.
One of the proven ways to screen patients is to
combine screening procedures with services that the
patients need and want. Mature women are either in
the child-bearing years or post menopausal. We need
to look at these groups separately.
The sexually active young woman is likely to be
seen in a private office or a public clinic for either
contraception or prenatal care. At that time she is
very likely to have a Pap smear and pelvic examina
tion done: in fact, it would be difficult for her to
avoid it. Consequently, these patients have cancer
screening tests done as an ancillary service, not
because this is their primary motivation for seeking
care. In order to continue to get the care she wants,
this type of patient is given return appointments and
will have repeat examinations and smears done.
If these young, sexually active women have an
abnormal smear, follow-up examination is usually
recommended. Consequently, the patients referred to
our Anaplasia Clinic are most commonly drawn from
this group. It is not difficult to do effective cancer
screening if you are providing a service that patients
desire and will seek out.
The post-menopausal woman of 65 who comes
in bleeding from a Stage II 1-b cancer of the cervix
does not fall into any of the categories related to
pregnancy. All too often she gives a history of having
her last encounter with a physician at the time of her
last delivery some 30 or more years previously. Why
don't these patients come in for examination') We
must examine the motivation and understanding of
the medically-indigent, middle-aged, and post-meno
pausal woman, since this is the group that has
the greatest need for cancer screening and also shows
the poorest utilization of cancer-screening services.
Sociologists tell us that motivation in medically
indigent patients is related to many factors (2, 3).
Fear of surgery, fear of cancer, and ultimately, fear or
death are important. The pressing problems of im
mediate day-to-day life such as obtaining sufficient
food, clothing, and adequate shelter often preclude
concern for a possible future problem which could be
prevented by such measures as cancer screening.
Lack of knowledge about the availability of screening
procedures and their possible significance is impor
tant, but although patients often are aware at some
level of these measures, they still do not take action.

If patients are to be convinced that they should seek
medical care when they do not have symptoms, they
must be made aware that the disease in question can
affect them. They must also be convinced that the dis
ease is curable and prevention is better than treat
ment for the active disease, even though cure is likely.
One of the common reasons given for not seek
ing a Pap smear is that the patient feels well and
equates the lack of symptoms with good health. Most
patients in this age group are aware that cancer
screening examinations are available. However, some
patients are afraid that if cancer is found, an opera
tion may be recommended. In one survey, many of
the patients interviewed felt that cancer was essential
ly incurable and therefore there was little to be gained
by finding out the bad news earlier than necessary.
Other patients feel that the test may be painful or that
they will be subjected to indignities in a clinic situa
tion. Fear that surgery will cause some interference
with sexual function is a common concern. These
beliefs and attitudes have been found consistently
in ghetto populations by numerous surveys (3).
The woman who is asymptomatic must first
learn about the availability of cancer screening. The
commonly used mass media such as radio, television,
and the press are not particularly effective in reaching
the ghetto population which is at highest risk. These
women are more often influenced by personal contact
with friends and relatives and by their own personal
experiences in health facilities (3).
The patient should then be made aware that
she is a possible candidate for the development of
cancer. Subsequently, she must be convinced that
treatment is effective and that she could benefit from
such treatment if it were necessary.
Utilization of services will be improved if the
clinic facilities are located in areas close to where the
patients live. Convenient hours must be arranged.
This often means having clinics open in the evening.
Finally, let us consider the woman who has
symptoms which might logically suggest the possibili
ty of cancer but who delays seeking care. We have
recently attempted to interview some of the patients
who were admitted with cancers which obviously
have been present for long periods of time in an effort
to learn more about the reasons why the delays oc
curred.* Fear of learning the diagnosis and fear of the
* (Oral communications from J. Jones, R. N., Department or
Nursing, Medical College of Virginia Hospital, Richmond. Vir
ginia).
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consequences of treatment rank high on the list of
reasons for patient delay. One nulliparous patient
stated, "I think if I had had a baby I would almost
have had to go to a doctor then, and maybe I would
have continued to go after that. I guess I just have
always been scared to go to the doctor because of
what he might find." At this point the patient
described some of her relatives who had died from
malignant disease. She went on to say. "My friends
and neighbors have been after me for a long time
to have an examination and so had my doctor.
I have been going to see him every three months
for blood pressure examination. He would offer to
do a pelvic examination each time I would go for
my yearly physical, but I would say no. My friend
had told me how painful the exam was and- I
would get nervous when I went to the doctor. He
was young and I just didn't feel right. He would ex
amine me otherwise and I always had no problems. It
is all my fault. If only I had listened to my friends and
my doctor."
Another example is that of a patient who had
bleeding for many months before seeking medical
attention. This patient was a very religious woman
who felt that her faith would heal her and probably
interpreted the presence of symptoms as some sort of
punishment. The patient stated. "When your time
comes to die. you must go. If the Lord had taken me
two weeks ago I would have been ready:· There is a
fatalistic attitude here as well as religious fervor.
Interestingly enough. the patient underwent sur
gery with complete removal of all visible tumor. She
had an uneventful recovery and was assured that she
had a good prognosis. In spite of the outcome and the
long delay on her part, she was very reluctant to give
any credit to the people who cared for her in the
hospital.
In the 1974 edition of its Manual of Standards
for Obstetrics and Gynecologic Services in Ac
credited Hospitals, the American College of Obste
tricians and Gynecologists makes the following
recommendation. "Good medical practice clearly
warrants the establishment of cytologic screening as a
hospital routine. It is therefore recommended that
regardless of the service to which she is admitted,
every female hospital patient who is age 18 or over or
is sexually active should have a pelvic examination
and a cervical-vaginal cytologic smear unless a
negative smear has been recorded within a year. To
implement this program, it is essential that hospitals
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make smears readily available and make every effort
to encourage their routine use."
Along this same line, there are now three states,
New York, Illinois, and Hawaii, that have passed
legislation making the Pap smear mandatory for all
women who are admitted to the hospital who tit into
the categories outlined in the ACOG recommen
dations (4). It seems likely that similar legislation
may be forthcoming in other states. There is no
reason why departments of obstetrics and gynecology
in any given hospital cannot exert pressure on the
hospital administration and the rest of the medical
staff to incorporate requirements such as these in
their hospital bylaws. Certainly a voluntary action of
this type would be more acceptable to most
physicians than to have it forced upon them by
legislative decree.
The question immediately arises as to who shall
perform these Papanicolaou smears on women who
are admitted to services other than Gynecology. The
nurse practitioner programs which are developing in
several medical centers may provide one answer to
this problem. A number of hospitals have employed
such individuals to do routine Pap smears on all
female admissions with good patient acceptance and
good results. Any patient is given the opportunity to
refuse to have a smear performed if she has some per
sonal objection. In addition. any woman who has had
a smear performed by her private physician within
the year prior to admission is not required to have a
smear done provided the cytology was negative (4 ).
A program of this kind would not solve the en
tire problem, but it could be a significant step in the
right direction. Patients admitted to hospitals con
stitute the captive population that is most accessible
and the one over which we as physicians have the
most control.
Summary. Patient education is an important
part of preventive measures and is most likely to be
effective when provided in a health-related setting.
Cancer-screening services are best utilized when they
are combined with other health services that the
patient needs or desires. Convenience of health ser
vices such as location of clinics, convenient hours.
and the attitude of health workers are significant fac
tors. Captive populations such as hospitalized
patients. inmates of institutions, individuals who
must take employment physical examinations. etc..
may be utilized to achieve more complete screening
of the population at risk. The influence of friends,
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neighbors, and relatives can not be overestimated.
Efforts must be made to utilize these influences in a
positive way. Finally, all physicians are urged to push
for routine Pap smears on female hospital admissions
as a voluntary program in their own hospitals.
REFERENCES
I. The American College of Obstetricians and Gynecologists
Newsletter 18:5, May 1974.

2. KEGEi.ES SS, KIRSCHT JP, HAEFNER DP, ET AL: Survey of
beliefs about cancer detection and taking papanicolaou tests.
Public Heailh Rep 80:815-823, 1965.

3. KEGEi.ES SS: Attitudes and behavior of the public regarding cer
vical cytology: current findings and new directions for research.

J Chronic Dis 20:911-922, 1967.

4. LEVINSON C, WALLACH RC: Cytologic screening by a nurse on
an in-hospital population. Obstet Gyneco/ 43:453-454. J 974.

Radical Hysterectomy for Carcinoma of the
Cervix*
JOHN J. MIKUTA. M.D.
Department of Obstetrics and Gynecology. Division of Gynecologic Oncology,
Hospital of the University of Pennsylvania School of Medicine. University
of Pennsylvania. Philadelphia. Pennsylvania

Radical hysterectomy refers to the removal of
the uterus and cervix and, in addition, to the removal
of the upper one-half to one-third of the vagina. the
parametria and the pelvic lymph nodes. This opera
tion, which is commonly called the Wertheim opera
tion. was actually first described by Clark in the
United States and Ries in Germany. Wertheim's
original operation for carcinoma of the cervix con
sisted only of a partial parametrial removal and
removal of the upper one-third of the vagina. It did
not include pelvic lymphadenectomy or the removal
of the lateral portions of the parametria.
The early efforts at radical hysterectomy for cer
vical cancer resulted in operative and surgical mor
tality in the range of 25-75%. In 1903. when it
became obvious that radiation therapy. available
then only in the form of radium, was effective for the
control of cervical cancer. clinicians abandoned the
radical hysterectomy procedure in favor of this
limited form of radiation. A few individuals persisted
in performing the operation, and in I 935. the British
gynecologist and surgeon, Victor Bonney, reported
on 500 consecutive patients on whom he had done
radical hysterectomy. His operative mortality was
16%.
In 1939, Dr. Joseph Meigs of Boston decided to
take a second look at the radical hysterectomy
procedure in view of some of the technical advances
which had occurred in medicine, primarily in the
areas of blood transfusion, anesthesia, antibacterial
* Presented by Dr. Mikula at the 46th Annual McGuire Lec
ture Series. December 6. 1974. at the Medical College or Virginia.
Richmond.
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chemotherapy. and improvement in pre and
postoperative care. Between 1939 and 1951, Meigs
performed I 00 consecutive radical hysterectomy
operations without a single surgical mortality. This
astounding feat provided the impetus in the United
States for a revision of thinking about this procedure
in the post-World War II era.
Meigs also defined the advantages of utilizing
radical hysterectomy in preference to radiation
therapy for cervical cancer. These are as follows:
I. There can be no tumor recurrence in the
cervix itself.
2. There can be no new tumor growths in the
cervix or upper vagina.
3. The problem of radio-resistant tumors is
avoided.
4. There can be no radiation injuries to the
bowel or the bladder.
In addition to the advantages listed by Meigs.
two other important factors can be considered as
helpful. The first of these is the ability to preserve
ovarian function in young women. The incidence of
metastasis to the ovary in a patient with early car
cinoma of the cervix is negligible, and it is possible.
by using radical surgery to preserve at least one
ovary. to avoid the onset of the climacteric. The sec
ond aspect is that the gynecologic oncologist will
know the extent of the disease as reported to him by
the pathologist after thorough study of the removed
specimen. From this not only will the prognosis be
known but also additional therapy can be considered.
Also. there are several clinical situations in
which. given equally available expert radiation
41
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therapy and radical pelvic surgery personnel and
facilities. one might elect a radical hysterectomy
approach. These are as follows:
I. Previous pelvic surgery (supravaginal or
total hysterectomy)
2. Presence of adnexal mass or masses. or
previous pelvic inflammatory disease
3. Diabetes mellitus
4. Pregnancy
5. Radiophobia
Appreciating what has already been stated with
regard to the advantages as well as the indications for
the use of radical hysterectomy and pelvic
lymphadenectomy. there are three significant limiting
features:
I. The medical condi1ion of 1he pa1ie111. This is
primarily related to the patient's general condition.
her age. obesity. and the presence of underlying car
diovascular and other diseases which might inlluence
the development of signiticant operative and
postoperative complications.
2. The 1ype and e.\"lenl of 1he malignancy 11·hic/1 is
being 1rea1ed. In cervical carcinoma. one of the
limiting factors is the extent of the disease and the
degree of its parametrial infiltration. From a clinical
standpoint. cancers of the cervix favorable for a
radical hysterectomy are clinical Stage 1-a. minimal
to moderate-siLed lesions which are 1-b. or very early
Stage II-a or Stage 11-b tumors. More extensive local
disease increases the probability of inadequate sur
gery as well as the risk of cutting through the tumor
at the time of operation. Similarly. the presence or
any tumor which is spread beyond the pelvic area in
the abdomen. particularly lymphatic involvement of
the para-aortic nodes or liver. is considered a con
traindication to radical hysterectomy approach as is
the finding of any distant metastasis during the
preoperative oncologic evaluation. Finally. radical
hysterectomy may be utiliLed in patients "ho have
minimal. central. post-radiation recurrence in which
the lesion has not extended to the bladder and rec
tum. This operation. under proper circumstances. is
preferable to the more extensive and complicated
procedure of pelvic exenteration.
3. The auailabilily of a surgeon 10 pe1fom1 radical
hysleree/omy. This factor in general provides the
greatest limitation to the surgical approach. since
during the standard gynecologic residency program.
there is neither the time nor the experience available
in the performance of radical pelvic surgery for the

resident to develop the necessary skills. Similarly, in
the routine practice of gynecology. a physician will
not have sufficient numbers of such patients to main
tain his operative expertise and capability. This
limitation is gradually being overcome by the
development of training programs in gynecologic on
cology which include training in the performance of
radical pelvic procedures. The identification and
utilization of the gynecologic oncologist who can per
form such procedures and who limits his area of
specialization to the treatment of gynecologic cancer
and its problems. is now a reality. A certifying board
in gynecologic oncology has been developed and in
dividuals are being recognized for skill in this par
ticular area. In addition. training programs are now
available throughout the country for individuals
already qualified in obstetrics and gynecology. They
can receive additional training for two years to
develop these skills.
Let us turn to some of the improvements which
have occurred in the results with radical hysterec
tomy in the management of cervical carcinoma. As
mentioned earlier. the operative and surgical mortali
ty was one of the major limiting factors in this
procedure. Since Meigs· original series. other writers
in recent times have reported series or patients on
whom radical hysterectomy was carried out with
minimal mortality. The inevitable catastrophe will
occur from time to time when the surgeon. at times
overstepping the bounds of good judgement. under
takes radical pelvic surgery on a patient and has an
unfavorable result. In general. the operative and sur
gical mortality should be in the range of 0.5%.
Scrupulous attention must be given to the
thorough preoperative evaluation of the patient. not
unly from the standpoint of her disease process so
that an operation of this type will not be attempted
on a patient with distant metastatic disease. but also
attention must be given to the general physical condi
tion of the patient. primarily her cardiovascular.
pulmonary. and renal systems. Infection of the
urinary system must be brought under control prior
to surgery. The operation itself must be meticulously
carried out with the knowledge of the extent or the
operation, the patient's condition. and possible
complicating factors well known to a competent
medical anesthesiologist. Careful dissection or the
pelvis with specific care around the large vessels
and ureters will insure a much lower incidenct: or
significant vascular and urinary tract complications
which are the chid" intra-operative problems. Finally.
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careful attention to the details of postoperative care
are essential to avoid the problems associated with
pulmonary, bowel, and urinary areas and to reduce
the incidence of thromboembolic phenomena in these
patients. For more detailed descriptions of these
areas of importance in the pre and postoperative
care, one's attention is directed to Nelson's Atlas of
Radical Pelvic Surgery.*

The major problem creating morbidity with
radical hysterectomy for cervical carcinoma is
associated with the urinary tract. While Meigs listed
among the advantages of radical hysterectomy the
avoidance of radiation complications to the bowel
and bladder, it became evident that there was a
significant morbidity associated with these structures
from radical hysterectomy. In reviewing all of the
complications associated with radical hysterectomy
at the Hospital of the University of Pennsylvania. in
an unselected group of radical hysterectomy
procedures, the greatest number, almost 50%, had
complications associated with urinary tract. These
were chiefly urinary tract infections, ureteral and
vesical fistulas, and postoperative bladder dysfunc
tion.
Let us look specifically at the problem of
uretero-vaginal fistula. The incidence of uretero
vaginal fistula as reported by Meigs varied from 10 to
15%. A significant improvement in the uretero
vaginal fistula rate was reported by Green, who
found that the incidence of this complication could
be reduced to approximately 4% by leaving the
urethral catheter in the bladder for a minimum of 6
weeks following the operation. It was felt that this
maneuver kept the ureteral bed in a more stable posi
tion and allowed better healing and vascularization.
In 1966, Green also described a technique of ureteral
suspension in which the ureter is approximated by
several sutures to the superior vesical artery from the
origin of this vessel to the ureterovesical junction. In
his original report, he found only one fistula in 65
patients. This experience has been repeated in other
centers, and it has been substantiated as an effective
and simple method of reducing the uretero-vaginal
fistula rate. This complication instead of being in the
range of 10 to 15%, is now reported in the range of
I to 2%.
Rather than keeping the uretheral catheter in
position in the bladder for a long period of time, it
• James Nelson, Jr., A rlas of Radical Pelvic Surgery.
Appleton, New York, 1969.
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has been the practice at the Hospital of the University
of Pennsylvania to evaluate the bladder prior to and
after operation by the use of cystometry. A
baseline measurement of bladder function is ob
tained prior to surgery, and, on approximately day 9
or 10 following surgery, a repeat cystometric evalua
tion is carried out. Frequently the bladder will be
found to be of the autonomous neurogenic type,
where there is absence of the sensation of filling as
well as failure of the bladder to accommodate to fill
ing. If attention is not paid to this alteration in vesical
function, the result will be overdistention and
overflow incontinence. Generally by the 10th to 20th
day after surgery there will be a gradual return of
function toward normal, first with the return of the
sensation of filling and the desire to void, and later a
correction of the detrusor function where accom
modation to filling and maintainance of low pressures
develop until the patient has the proper desire to
void.
Other aspects aimed at reducing urinary tract
morbidity are the reduction of infection and the
avoidance of trauma. There must be clearance of
preoperative urinary infection, gentle and minimal
handling of the ureter during the procedure, with an
effort to preserve its blood supply as much as possi
ble. and finally pre and postoperative administration
of appropriate systemic antibiotics. Local intravesical
antibiotics may be utilized through a triple-lumen
Foley catheter (Neosporinig G-U irrigant). Another
approach is to carry out the suprapubic drainage
technique to reduce possible contamination of the
bladder seen so often with the use of the urethral
catheter.
An added factor in reduction of uretero-vaginal
fistula is the use of techniques to reduce the collec
tion of serum and lymph in the retroperitoneal space.
This was originally described by the Chinese using
the paracoccygeal route. More recently, Welch, Pratt.
and Symmonds applied closed-suction techniques to
the retroperitoneal area via the abdominal wall. This

TABLE I
Cancer of Cervix 1955-1969 Radical Hysterectomy Stage
of Disease
28
Stage 1-a
62
Stage 1-b
8
Stage 11-a
4
Stage 11-b
Total

102
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TABLE 4
Cancer of Cervix HUP 1955-1969 (5-yr. survival)

TABLE 2
Radical Hysterectomy 5-yr. survival
Cancer of Cervix HUP 1955-1969
Stage I
Stage II

Total
90
12

L
75
8

Stage

%
83.3
66.6

decreases the amount of materials which might
become infected, reduces the possibility of
lymphocyst formation, and also may improve the
ability of the ureter to maintain its blood supply. The
results associated with radical hysterectomy as
primary treatment for cervical cancer at the Hospital
of the University of Pennsylvania are noted in Tables
I, 2, 3, and 4. Comparison of statistics from one
institution to another regarding the operable stages
of cervical cancer show that radiation and surgery
can provide approximately the same 5-year survival.
The surgical proponents have always had the advan
tage. especially where absolute survival figures are
considered, since the surgical patients are always
better selected, usually in better medical condition,
and more likely to survive five years.
Finally, it is important to consider some areas
for the future with regard to radical hysterectomy in
the management of cervical carcinoma. First. the use
of cytological vaginal screening is providing the
gynecologic oncologist with younger patients who
have an earlier disease to treat. These patients are
very favorable surgical candidates. Second, there is
an unanswered question regarding the management
of patients who are found at radical hysterectomy to
have pelvic lymph nodes involved with tumor.
Presently most of these patients are receiving
postoperative irradiation therapy to the pelvis. The
advisability of combining radical surgery with radical
radiation must not only be measured in survival
results but also in terms of the seriousness of the com
plications that frequently follow such combined
therapy. Third, one might question the advisability of

1-a
1-b
II-a
11-b

Nega1ive nodes
%
L
24/27'
45/50'
3/4
2/2

88.8
90.0
75.0
100.0

Positive nodes
L
%
0/1
6/12
1/4
2/2

0
50.0
25.0
100.0

* one patient in each group lost-considered dead

abandoning the procedure when para-aortic lymph
nodes are found to be involved with tumor. The ques
tion which needs to be answered is whether such
patients are better handled by carrying out the radical
hysterectomy procedure, where technically feasible,
and then adding pelvis and para-aortic irradiation
postoperatively. Answers to the second and third
problems need to be obtained, and this probably can
best be accomplished through national cooperative
study groups.
Finally. if cervical cancer detection programs
continue to increase the findings of preinvasive
malignancy. with the eradication of invasive cervical
cancer. one wonders whether the case load will be
sufficient for the maintainance of large numbers of
experts in radical pelvic surgery among gynecologic
oncologists. Only time will answer this question.
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Control of Endometrial Cancer
SAUL B. GUSBERG. M.D.. D.SC.

Professor and Chairman. Deparunent of Obstetrics and
Gynecology. Mount Sinai Medical School. Nell' York. New
York
Epidemiologic studies of this disease may offer
etiologic clues and help us recognize high-risk factors. Of
special interest in this respect is the infrequency of en
dometrial cancer in Asian women and the increase in its in
cidence in migrants to Western countries.
The definition of high-risk factors in the peri
menopausal years and the possibility of screening them
f
by ambulatory aspiration curettage could of er the
possibility of prophylactic measures that could interrupt
the progression to invasive cancer. The recognition of en
dometrial cancer precursors. especially adenomatous
hyperplasia. is critical in such surveillance and can lead to
control in the same manner that the diagnosis of cervix
cancer precursors has contributed to the steady decline in
mortality from that disease.
Modern steroid metabolic technology has enabled us
to gain significant insights into the problems of hormone
sensitivity of endometrial cancer and offers promise of
allowing us to make real therapeutic advances in this area.
The recognition of adrenal androstenedione as the
postmenopausal estrogen precursor and the techniques of
quantifying estradiol receptor sites in target cells will be
very important in these studies.

The Diagnosis and Management of
Cervical Intraepithelial Neoplasia
RICHARD T. UPTON, CAPT MC USN

Chairman, Department of Obstetrics and Gynecology. Naval
Regional Medical Center, Portsmouth. Virginia
Carcinoma of the uterine cervix continues to be a ma
jor health problem to the women of this country. In order
to reduce the morbidity and mortality from this preven
table problem, it is important that we develop and utilize

MCV QUARTERLY 11(1):45-46, 1975

effective techniques of early diagnosis and treatment of the
disease in its intraepithelial stage.
For more than two decades the Papanicolaou
cytosmear technique has been available to clinicians as a
screening test for cervical neoplasia. For many years the in
dicated follow-up evaluation of abnormal Papanicolaou
smears suggesting cervical neoplasia was to perform a cold
knife conization biopsy of the cervix of these patients with
abnormal cytosmears. With the increasing acceptance in re
cent years of the colposcope as an adjunctive diagnostic
tool. it is now possible for most clinicians to perform, or
have performed on their patients with abnormal cerviclll
cytosmears. a thorough colposcopic examination of the cer
vix and vagina and to obtain directed biopsies from areas
of abnormality as indicated by direct, magnified vision. Ex
amination of the endocervical canal by direct vision so far
as possible and by endocervical curettage in each case are
important procedures in the proper evaluation of these
patients. By these careful adjunctive diagnostic techniques.
it is possible to definitively diagnose the degree and extent
of virtually all cervical intraepithelial neoplastic processes.
In the absence of neoplastic changes in the endocer
vical curettings. those patients with biopsy diagnosis of
varying grades of intraepithelial neoplasia are then man
aged according to the age of the patient and the severity of
the dysplastic process. The patients with mild or moderate
dysplastic changes are treated with cervical cryotherapy us
ing either freon or nitrous oxide delivered by any of several
currently available and acceptable machines. Upwards of
90% of these early dysplastic changes can be reversed or
eradicated by this technique. For those patients with more
advanced grades of dysplasia or carcinoma in situ,
management should take into consideration their reproduc
tive interests. Those who have no further desire for
pregnancy may be managed by hysterectomy with preserva
tion of normal ovaries. If conservation of childbearing
capability is desired, then treatment with cryotherapy or
therapeutic cold-knife conization followed by careful
cytologic and colposcopic evaluation is in order. The preg
nant patient with cervical intraepithelial neoplasia may be
managed with careful colposcopic delineation of the
magnitude and extent of the neoplastic lesion, visualization
of 360 ° of normal endocervical epithelium. and assurance
that the biopsy was taken from the most abnormal area of
the cervix. The pregnancy may then be maintained without
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further therapy or diagnostic efforts. vaginal delivery ac
complished. and then careful follow-up and definitive
management in the postpartum period carried out.
For those patients with endocervical curettings con
taining evidence of dysplasia or carcinoma in situ and/or
with cervical biopsies reported as invasive carcinoma.
definitive management appropriate to the patient and the
staging is then carried out without conization. For those
patients with evidence of dysplasia or carcinoma in situ
in the endocervical curettings but with the biopsy
diagnosis of cervical intraepithelial neoplasia. and those
patients in whom endocervical curettings could not be
obtained, a cold-knife conization is indicated. This may
then be followed immediately after definitive diagnosis.
either the same day or within 48 hours. by definitive
management as indicated by the stage of the neoplastic dis
ease.
Many techniques have been used over the years for the
treatment of cervical intraepithelial neoplastic processes.

These include the use of varying degrees of surgical exci
sion. radiation therapy. ultrasound, and extremes of
temperature by either cauterization or freezing techniques.
In recent months. the use of the Carbon Dioxide Surgical
Laser has come under investigation as a possible means of
colposcopically directed, precise, laser surgical excision of
the areas of cervical epithelial abnormality. This technique
offers considerable promise. and the preliminary studies are
being prepared for presentation in the near future.
The effectiveness of these forms of management. as
briefly discussed above, are dependent upon the co
operativeness of the patient to obtain periodic health
evaluations. the alertness and willingness of clinicians to
obtain at least annual cervical cytosmears on their female
patients. and the increasing availability of the trained
colposcopist to define and refine the adjunctive diagnostic
techniques and precise management that more appropriate
ly fit the patient's needs as dictated by the degree of her
neoplastic process.

Breast: Non-Cancerous Diseases
JUNE 29-JUL Y 3, 1976 STRASBOURG

4TH INTERNATIONAL SYMPOSIUM ON SENOLOGY
European Association of Radiology ( E.A.R.)

I. STUDY GROUPS

(Invited lectures, Discussions)
A. Investigation Methods
Physical examination, Diaphanoscopy, Radiography, Thermography, Echography
Cytology, Histology
Biochemistry, Endocrinology
Psychology, Computer analysis
8.

Mastopathies
Cystic mastopathies, Galactorrhea. Discharges, ...
Fibroadenoma, Adenosis, Fibrosis, lnvolutive States ...
Pre-cancerous Diseases: Dysplasia, Phyllodes, Non-invading Carcinomas ....

C. Lactation
Maternal Suckling
Pathology, Psychology, Sociology
II. COMMUNICATION, CONFERENCES

a. Topics of Study Groups A, B, C
b. Infections, Traumatisms, Infarcts, Lipoma, Necrosis, Thrombophlebitis, ..
Pathology of Skin, Aerola, Nipple.
c. Malformations, Ungracefulness, Amazonism, ...
Plastic Surgery
d. Breast Pathology in Man, Androgyny
{Continued on page 51)
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"Tolerance is an ever-present hazard to continued
use of narcotics....The very first dose diminishes the
effects of subsequent doses."1 And, as increasing
amounts of narcotics are required to control pain, distressing adverse effects- lethargy, hypotension, con
stipation, etc. -can needlessly debi I itate the patient.
l.Sadove, M. S.: A look at narcotic and non-narcotic analgesics, Postgrad.

Med. 49,102, June 1971.

how big a dose will now
bring relief if it is Talwin?
Chances are, the same 50 mg. Talwin Tablet you
prescribe originally will continue to provide good pain
relief. Talwin can be compared to codeine in anal
gesic efficacy: one 50 mg. tablet appears equivalent
in analgesic effect to 60 mg. (1 gr.) of codeine. How
ever, patients receiving Talwin Tablets for prolonged
periods face fewer of the consequences you've come
to expect with narcotics. There should be fewer
"adverse effects " on her way of life.
Tolerance rare: Tolerance to the analgesic effect of
Talwin Tablets is rare.
Dependence rare: During three years of wide clinical use, there
have been a few reports of dependence and of withdrawal symp
toms with orally administered Ta/win. Patients with a history
of drug dependence should be under close supervision while
receiving Ta/win orally.

In prescribing Ta/win for chronic use, the physician should
take precautions to avoid increases in dose by the patient and
to prevent the use of the drug in anticipation of pain rather
than for the relief of pain.*
Generally well tolerated by most patients•: Infrequently causes
decrease in blood pressure or tachycardia; rarely causes respi
ratory depression or urinary retention; seldom causes di�rrhea
or constipation. Acute, transient CNS effects, described 1n
.
product information on following page, have occurred in rare
instances following the use of Talwin Tablets. If dizziness,
lightheadedness nausea or vomiting are encountered, these
effects may dec(ease or disappear after the first few doses.
•see important product information. on next page for ad�erse reactions, patient
selection, prescribing and precautionary recommendat1ons.
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in chronic pain

of moderate to severe intensity

TalMn::.:1.
Penta
zoc�!!!!

in chronic
pain of
111oderate to
severe
intensity

Talwin® Tablets brand of pentazocine (as hydrochloride)
Analgesic for Oral Use
Indication: For the relief of moderate to severe pain.
Contraindication: Talwin should not be administered to patients
who are hypersensitive to it.
Warnings: Drug Dependence. There have been instances of psy
chological and physical dependence on parenteral Ta/win in pa
tients with a history of drug abuse and, rarely, in patients without
such a history. Abrupt discontinuance following the extended use
of parenteral Ta/win has resulted in withdrawal symptoms. There
have been a few reports of dependence and of withdrawal symp
toms with orally administered Ta/win. Patients with a history of
drug dependence should be under close supervision while receiv
ing Ta/win orally.
In prescribing Ta/win for chronic use, the physician should take
precautions to avoid increases in dose by the patient and to pre
vent the use of the drug in anticipation of pain rather than for the
relief of pain.
Head Injury and Increased lntracrania/ Pressure. The respiratory
depressant effects of Talwin and its potential for elevating cerebro
sp,nal fluid pressure may be markedly exaggerated in the pres
ence of head injury, other intracranial lesions, or a preexisting
increase in intracranial pressure. Furthermore, Talwin can pro
duce effects which may obscure the clinical course of patients
with head injuries. In such patients, Talwin must be used with
extreme caution and only if its use is deemed essential.
Usage in Pregnancy. Safe use of Talwin during pregnancy (other
than labor) has not been established. Animal reproduction studies
have not demonstrated teratogenic or embryotoxic effects. How
ever, Talwin should be administered to pregnant patients (other
than labor) only when, in the judgment of the physician, the po
tential benefits outweigh the possible hazards. Patients receiving
Talwin during labor have experienced no adverse effects other
.than those that occur with commonly used analgesics. Talwin
should be used with caution in women delivering premature
infants.
Acute CNS Manifestations. Patients receiving therapeutic doses
of Talw1n have experienced, in rare instances, hallucinations (usu
ally. visual), disorientation, and confusion which have cleared
sportaneously within a period of hours. The mechanism of this
. reacticin. is n.ot known. Such patients should be very closely ob
served and vital signs checked. If the drug is reinstituted it should
be done with caution since the acute CNS manifestations may recur.
Usage in Children. Because clinical experience in children under
12 years of age is limited, administration of Talwin in this age
group 1s not recommended.
Ambulatory Patients. Since sedation, dizziness, and occasional
euphoria have been noted, ambulatory patients should be warned
not to operate machinery, drive cars, or unnecessarily expose
themselves to hazards.
Precautions: Certain Respiratory Conditions. Although respiratory
depression has rarely been reported after oral administration of
Talw1n, the drug should .be administered with caution to patients
w.1th respiratory depression from any cause, severely limited res
piratory reserve, severe bronchial asthma and other obstructive
respiratory conditions, or cyanosis.
Impaired Renal or Hepatic Function. Decreased metabolism of the
drug by th
. e liver. in extensive liver disease may predispose to
acc.entuat1on of side effects. Al.though laboratory tests have not
indicated that Talw1n causes or !ncreases renal or hepatic impair
ment, the. dru& should be administered with caution to patients
with such impairment .
Myocardial Infarction. As . with all drugs, Talwin should be used
with caution 1n patients with myocardial infarction who have nau
sea or vomiting.
Biliary Surgery. Until further experience is gained with the effects

of Talwin on the sphincter of Oddi, the drug should be used w
caution in patients about to undergo surgery of the biliary tr,
Patients Receiving Narcotics. Talwin is a mild narcotic antagori
Some patients previously given narcotics, including methadone'
the daily treatment of narcotic dependence, have experier.,
withdrawal symptoms after receiving Talwin.
CNS Effect. Caution should be used when Talwin is administeic
to patients prone to seizures; seizures have occurred in a fews�.
patients in association with the use of Talwin although no ca[
and effect relationship has been established.
Adverse Reactions: Reactions reported after oral administration
Talwin include gastrointestinal: nausea, vomiting: infrequen·
constipation; and rarely abdominal distress, anorexia, diarrhe·
CNS effects: dizziness, lightheadedness, sedation, euphoria, he;
ache; infrequently weakness, disturbed dreams insomnia SJ
cope, visual blurring and focusing difficulty, hailucinations (Sf
Acute CNS Manifestations under WARNINGS); and rarely trem;
irritability, excitement, tinnitus. Autonomic: sweating; infreque�
flushing; and rarely chills. Allergic: infrequently rash; and rare
urticaria, edema of the face. Cardiovascular: infrequently di
crease in blood pressure, tachycardia. Hematologic: rarely di
pression of white blood cells (especially granulocytes), usua
rev.ersible and usually associated with diseases or other dru,
which am. known to cause such changes, moderate transi�·
eosinoph1l1a. . Other: rarely respiratory depression, urinary ret�
t1on, toxic epidermal necrolysis.
Dosage and Administration: Adults. The usual initial adult dose
1 tablet (50 mg.) every three or four hours. This may be increase
to 2 tablets (100 mg.) when needed. Total daily dosage should r1
exceed 600 mg.
When antiinflammatory or antipyretic effects are desired in add
t1on to analgesia, aspirin can be administered concomitantly wit
Talwin.
Children Under 12 Years of Age. Since clinical experience in cli
dren under 12 years of age is limited, administration of Tai�
in this age group is not recommended.
Dura_tion of Therapy. Patients with chronic pain who have receive
Talw1n orally for prolonged periods have not experienced witt
drawal symptoms even when administration was abruptly discor
tinued (see WARNINGS). No tolerance to the analgesic effect ha
been observed. Laboratory tests of blood and urine and of liver ari:
kidney function have revealed no significant abnormalities afte
prolonged administration of Talwin.
Overdosage: Manifestations. Clinical experience with Talwin ove1
dosage has been insufficient to define the signs of this conditioo
Treatment. Oxygen, intravenous fluids, vasopressors, and othe
support1ve measures should be employed as indicated. Assistec
or controlled ventilation should also be considered. Althougl
nalorph1ne an.d levallorphan are not effective antidotes for respira
tory . depression due to overdosage or unusual sensitivity tc
Talw1n, paren.teral na.loxone (Narcan®, available through En ·
Laboratories) 1s a spec1f1c and effective antagonist.
Talwin 1s not subJect to narcotic controls.
How.Supplied: Tablets, peach color, scored. Each tablet contains
Talw1n (brand of pentazocine) as hydrochloride equivalent lo
50 mg. base. Bottles of 100.
Winthrop Laboratories, New York, N.Y. 10016 @�1t1l
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e. Computer Analysis, Nomenclatures, Codifications,
f. Comparative Psychology, Veterinary Art, Ethology
g. Breast Functions (maternity, sexuality, aesthetics): arts, literature, fashion, history, ...
h. Miscellaneous
III.

POST-UNIVERSITY TEACHING

(Pre-Symposium Meetings on techniques and all applications)
I. Journees Nationales on ECHOGRAPHY
(French Society of Echography)
June 28-29, 1976
2. Post-University Courses onTHERMOGRAPHY
(European Association ofThermography)
June 28, 1976
3. Post-University Courses on XEROGRAPHY
June 28, 1976
IV.

SCIENTIFIC EXHIBITION

V. TECHNICAL EXHIBITION
SimultaneousTranslation: English, French, and German, in all rooms.
Program and Information:
SYMPOSIUM SEIN 1976-PROF. CH. GROS
PALAIS DES CONGRES
67 STRASBOURG-FRANCE
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A service to medical education from A. H. Robins:

Series

on physical examination
of the abdomen·

l
es

The A H Robins G 1 Series consists of six book
lets. designed to provide a Quick yet comprehen·
s1ve review of basic procedures and practices in
G I medicine w11h particular emphasis on the
phys1catexam1na11on as performed 1n !he office or
...
at bedside If you have teaching respons1b1l1t1es.
hmlled Quan1111es are available Pan 1 lnspect,on
Part 2 Pa/pat1on. Pan 3 Percuss,on. Pan 4 Auscultation. Part 5
Abdominal Pam and Part 6 01fferent1al Diagnosis of Abdominal
Disorders. Wnte to The Medical Department A H Robins Company
1407 Cummings Dnve. Richmond Virginia 23220

Normally palpable organs:

the edge of the liver descending,
on inspiration, below the costal
margin (A): the lower pole of the
right kidney (BJ, the abdominal
aorta (CJ; the descending colon
and the sigmoid (DJ: the ascend
ing colon (El: and occasionally
the bladder (though rising of
this organ beyond the pubis
does not necessarily 1nd1cate
disease)
Impossible to outline unless
diseased. distended or enlarged
the gallbladder. pancreas.
stomach. small intestine . trans
verse colon and spleen
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Brief summary. Adverse Reactions. Blurring of v1s1on. dry mouth,
d1fl1cult urination. and flushing or dryness of the skin may occur
on higher dosage levels. rarely on usual dosage Contra1nd1ca11ons Glaucoma: renal or hepatic disease. obstructive uropathy
(for example. bladder neck obstruction due to prostat1c hyper
trophy). or hypersens1t1v1ty to any of the ingredients
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netOre Prescribmk, please consult
complete product information, a summary of which follows:
.
Indications: Tension and anxiety
states, somatic complaints which are
concomitants of emotional factors; psy
choneurotic states manifested by tension,
anxiety, apprehension, fatigue, depres-.
sive symptoms or agitation; symptoniat1c
relief of acute agitation, tremor, delirium
tremens and hallucinosis due to acute
alcohol withdrawal; adjunctively in skele
tal muscle spasm due to reflex spasm to
local pathology, spasticity caused by .
upper motor neuron disorders, athetos1s,
stiff-man syndrome, convulsive disorders
(not for sole therapy).
Contraindicated: Known hypersensi
tivity to the drug. Children under 6
months of age. Acute narrow angle glau
coma; may be used in patients with open
angle glaucoma who are receiving appro
priate therapy.
Warnings: Not of value in psychotic
patients. Caution against hazardous
occupations requiring complete mental
alertness. When used adjunctively in con
vulsive disorders, possibility of increase
in frequency and/ or severity of grand mal
seizures may require increased dosage of
standard anticonvulsant medication;
abrupt withdrawal may be associated
with temporary increase in frequency
and/ or severity of seizures. Advise
against simultaneous ingestion of alcohol
and other CNS depressants. Withdrawal
symptoms (similar to those with barbitu
rates and alcohol) have occurred follow
ing abrupt discontinuance (convulsions,
tremor, abdominal and muscle cramps,
vomiting and sweating). Keep addiction
prone individuals under careful surveil
lance because of their predisposition to
habituation and dependence. In preg
nancy, lactation or women of childbearing
age, weigh potential benefit against
possible hazard.
Precautions: If combined with other
psychotropics or anticonvulsants, con
sider carefully pharmacology of agents
employed; drugs such as phenothiazines,
narcotics, barbiturates, MAO inhibitors
and other antidepressants may potentiate
its action. Usual precautions indicated in
patients severely depressed, or with latent
depression, or with suicidal tendencies.
Observe usual precautions in impaired
renal or hepatic function. Limit dosage to
smallest effective amount in elderly and
debilitated to preclude ataxia or over
sedation.
Side Effects: Drowsiness, confusion,
diplopia, hypotension, changes in libido,
nausea, fatigue, depression, dysarthria,
jaundice, skin rash, ataxia, constipation,
headache, incontinence, changes in sali
vation, slurred speech, tremor, vertigo,
urinary retention, blurred vision. Para,
doxical reactions such as acute hyper
excited states, anxiety, hallucinations,
increased muscle spasticity, insomnia,
rage, sleep disturbances, stimulation
have been reported; should these occur
discontinue drug. Isolated reports of ne�
tropenia, jaundice; periodic blood counts
and liver function tests advisable during
long-term therapy.
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When, for example, despite counseling,
tension and anxiety continue to produce
distressing somatic symptoms

. Promnt action
1s a goocl reason to
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